<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine X</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine X</journal-id><journal-id journal-id-type="pmc-domain-id">3700</journal-id><journal-id journal-id-type="pmc-domain">vaccinex</journal-id><journal-title-group><journal-title>Vaccine: X</journal-title></journal-title-group><issn pub-type="epub">2590-1362</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10848012</article-id><article-id pub-id-type="pmcid-ver">PMC10848012.1</article-id><article-id pub-id-type="pmcaid">10848012</article-id><article-id pub-id-type="pmcaiid">10848012</article-id><article-id pub-id-type="pmid">38328274</article-id><article-id pub-id-type="doi">10.1016/j.jvacx.2024.100452</article-id><article-id pub-id-type="pii">S2590-1362(24)00025-1</article-id><article-id pub-id-type="publisher-id">100452</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Malik</surname><given-names initials="S">Shiza</given-names></name><email>shizzza874@gmail.com</email><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Asghar</surname><given-names initials="M">Muhammad</given-names></name><email>muhammad.asghar@biol.lu.se</email><xref rid="af010" ref-type="aff">b</xref><xref rid="af015" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Waheed</surname><given-names initials="Y">Yasir</given-names></name><email>yasir_waheed_199@hotmail.com</email><xref rid="af020" ref-type="aff">d</xref><xref rid="af025" ref-type="aff">e</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><aff id="af005"><label>a</label>Bridging Health Foundation, Rawalpindi, Punjab 46000, Pakistan</aff><aff id="af010"><label>b</label>Department of Biology, Lund University, Sweden</aff><aff id="af015"><label>c</label>Department of Healthcare Biotechnology, Atta-Ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), H-12, Islamabad, Pakistan</aff><aff id="af020"><label>d</label>Office of Research, Innovation, and Commercialization (ORIC), Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), Islamabad 44000, Pakistan</aff><aff id="af025"><label>e</label>Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos 1401, Lebanon</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding authors. <email>muhammad.asghar@biol.lu.se</email><email>yasir_waheed_199@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>30</day><month>1</month><year>2024</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">454559</issue-id><elocation-id>100452</elocation-id><history><date date-type="received"><day>3</day><month>7</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>07</day><month>02</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-08 12:25:11.200"><day>08</day><month>02</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab005"><p>Influenza virus has presented a considerable healthcare challenge during the past years, particularly in vulnerable groups with compromised immune systems. Therapeutics and vaccination have always been in research annals since the spread of influenza. Efforts have been going on to develop an antiviral therapeutic approach that could assist in better disease management and reduce the overall disease complexity, resistance development, and fatality rates. On the other hand, vaccination presents a chance for effective, long-term, cost-benefit, and preventive response against the morbidity and mortality associated with the influenza. However, the issues of resistance development, strain mutation, antigenic variability, and inability to cure wide-spectrum and large-scale strains of the virus by available vaccines remain there. The article gathers the updated data for the therapeutics and available influenza vaccines, their mechanism of action, shortcomings, and trials under clinical experimentation. A methodological approach has been adopted to identify the prospective therapeutics and available vaccines approved and within the clinical trials against the influenza virus. Review contains influenza therapeutics, including traditional and novel antiviral drugs and inhibitor therapies against influenza virus as well as research trials based on newer drug combinations and latest technologies such as nanotechnology and organic and plant-based natural products. Most recent development of influenza vaccine has been discussed including some updates on traditional vaccination protocols and discussion on next-generation and upgraded novel technologies. This review will help the readers to understand the righteous approach for dealing with influenza virus infection and for deducing futuristic approaches for novel therapeutic and vaccine trials against Influenza.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Influenza virus</kwd><kwd>Influenza virus infection</kwd><kwd>Therapeutics</kwd><kwd>Antiviral agents</kwd><kwd>Vaccines</kwd><kwd>Treatment</kwd><kwd>Novel therapeutic</kwd><kwd>Clinical management</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="k0050">CDC</term><def><p>Center for Disease Control and Prevention</p></def></def-item><def-item><term id="k0060">CTLs</term><def><p>Cytotoxic T Lymphocytes</p></def></def-item><def-item><term id="k0070">DAAs</term><def><p>Direct-Acting Antivirals</p></def></def-item><def-item><term id="k0080">FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term id="k0090">HA</term><def><p>Proteins Hemagglutinin</p></def></def-item><def-item><term id="k0100">LAV</term><def><p>Live-Attenuated Vaccines</p></def></def-item><def-item><term id="k0110">M1</term><def><p>Matrix 1 Protein</p></def></def-item><def-item><term id="k0120">M2e</term><def><p>Matrix protein two ectodomains</p></def></def-item><def-item><term id="k0130">miRs</term><def><p>Micro RNAs</p></def></def-item><def-item><term id="k0140">NA</term><def><p>Proteins Neuraminidase</p></def></def-item><def-item><term id="k0150">nAbs</term><def><p>Neutralizing Antibodies</p></def></def-item><def-item><term id="k0160">NP</term><def><p>Nucleoproteins</p></def></def-item><def-item><term id="k0170">PA Inhibitor</term><def><p>Polymerase Endonuclease Inhibitors</p></def></def-item><def-item><term id="k0180">RdRP</term><def><p>RNA-Dependent RNA Polymerase</p></def></def-item><def-item><term id="k0190">siRNAs</term><def><p>Small Interfering RNAs</p></def></def-item><def-item><term id="k0200">TLR</term><def><p>Toll-Like Receptor</p></def></def-item><def-item><term id="k0210">VLP</term><def><p>Virus-Like Particles</p></def></def-item><def-item><term id="k0220">WHO</term><def><p>World Health Organization</p></def></def-item></def-list></front><body><sec id="s0005"><title>Introduction</title><p id="p0590">Influenza viruses cause significant global health burden, and are highly contagious and easily spreading virus, which can lead to epidemic and even pandemic <xref rid="b0005" ref-type="bibr">[1]</xref>. Influenza viruses causes a mild disease, characterized by fever, nasal congestion, cough, and muscle aches, and does not require specific therapeutics for cure<xref rid="b0010" ref-type="bibr">[2]</xref>. However, severe disease mainly affects infants, pregnant women, and the elderly or immunocompromised individuals <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>. Annually one billion influenza cases occurs, resulting in approximately 3&#8211;5 million sever cases and around half a million death <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>. Influenza virus mainly transmitted by inhalation of viral particle suspended in aerosol or droplets and target the upper respiratory epithelial cells <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>.</p><p id="p0595">Biologically influenza virus is an RNA virus with eight segmented negative sense strains of RNA incorporated within a lipid envelope <xref rid="b0045" ref-type="bibr">[9]</xref>, belongs to family <italic toggle="yes">Orthomyxoviridae</italic> and contain at least three subtypes A, B, and C virus (IAV, IBV and ICV, respectively) <xref rid="b0050" ref-type="bibr">[10]</xref>. However, influenza virus rapidly mutates and has ability develop resistance against the antiviral compounds via different processes like antigenic shift (genome segment reassortment), and antigenic drift (genetic mutation) resulting in a new clads and subclades of influenza virus <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>. One such mutant type; caused by antigenic shift (genome segment reassortment), was notified back in 2009, namely, the H1N1 subtype of influenza that emerged from swine and caused an epidemic <xref rid="b0065" ref-type="bibr">[13]</xref>. Such genetic variations cause the frightening possibility of H5N1 avian flu causing viruses to gain the function of transmissibility between humans. Similarly, the rise of other avian influenza virus H5N1 (bird flu), H1N1 (swine flu) and H3N2 have caused significant health burden <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>. Thus making it pertinent for the scientific community to control their further spread and confine their proliferation among humans through the development of appropriate therapeutics against different strains <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>.</p><p id="p0600">Several therapeutic trials have been conducted in the past targeting influenza virus replication cycles, enhancing immune system responses, resisting the mutational abilities of viruses, and overcoming the resistance that develops against therapeutics in influenza viruses <xref rid="b0110" ref-type="bibr">[22]</xref>. A few candidate therapeutics have been approved by the Food and Drug Administration (FDA) such as amantadine, rimantadine, zanamivir, oseltamivir <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, while others are still in trails. These approved drugs mostly inhibits virus replication process within the host cell <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref> and reduce disease symptoms and severity. However, the influenza viruses have shown to slowly develop resistance against these drugs, which limits the time window and efficacy profile of approved drugs <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>.</p><p id="p0605">Vaccination against viral diseases is a cost-effective, efficacious, and rapid counter-response to control epidemic and pandemic <xref rid="b0150" ref-type="bibr">[30]</xref>. However, the strain-specific immunity and continuous viral genetic mutation remain a hurdle in universal vaccine design, especially in the case of the influenza virus <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>. The major structural features inquired in influenzas that make the vaccination efforts practical include the surface proteins hemagglutinin (HA), which induces fusion of the virus to sialic acid-containing receptors in host cells after the virion has attached to the cell surface and been endocytosed. The fusion process is how the HA fuses the virus envelope and the endosomal membrane to break it apart and release the virion's genetic segments into the cell's cytosol <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>. While the 2nd category of surface proteins neuraminidase (NA) acts as a receptor destroyer enzyme and plays roles in viral release and cellular transmission. Influenza A virus is further divided into subtypes based on which HA (out of 18) and NA (out of 11) they display on surface of their viral membrane (e.g., H1N1, H3N2, H5N1).</p><p id="p0610"><xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>. The currently licensed vaccines against influenza work either on the principle of inactivated or live attenuated vaccination protocols or those devised on principles of subunit vaccines which majorly incorporate the influenza viral particles such as surface proteins HA, and NA fragments <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>. Moreover, the vaccination design may involve two or three viral species leading to formulations of divalent, trivalent, and quadrivalent vaccine formulations incorporating multiple strain fragments <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>. It should be noted that the WHO has not detected any Yamagata lineage of influenza B since 3/2020 so it currently is recommending that this strain not be included in seasonal vaccine formulations <xref rid="b0190" ref-type="bibr">[38]</xref>. In this review, we have tried to briefly describe recent updates on influenza therapeutics and some of the important vaccination protocols and associated ongoing research trials worldwide.</p></sec><sec id="s0010"><title>Methodology</title><sec id="s0015"><title>Search Criteria</title><p id="p0615">A methodological research strategy has been adopted for this literature review to include data from diverse, recent, and most cited sources of research studies. Data was collected via a methodological literature search through various online sources including Google Scholar, PubMed, NIH (National Library of Medicine), Web of Science, European database, Springer, and Embase databases. Statistical and epidemiological results have been gathered from the official websites of the WHO, CDC, and FDA. The study inculcates original research articles, sections from books, letters to the editors, short and lengthy reviews, and some case studies published recently. For data on therapeutics against Influenza viruses, major search terms were &#8220;influenza virus&#8221;, &#8220;influenza virus disease&#8221;, &#8220;therapeutics against influenza&#8221;, &#8220;antiviral agents,&#8221; &#8220;vaccines against influenza&#8221;, &#8220;therapies against influenza&#8221;, &#8220;novel therapeutic approaches&#8221; while for vaccines against Influenza viruses, major search terms were &#8220;influenza virus&#8221;, &#8220;influenza virus biology&#8221;, &#8220;vaccines against influenza&#8221;, &#8220;novel vaccination trials&#8221; and &#8220;therapies against influenza&#8221;.</p></sec><sec id="s0020"><title>Inclusion and exclusion strategy</title><p id="p0620">The inclusion and exclusion criteria simply revolved around gathering data from original research articles, sections from books, letters to the editors, short and lengthy reviews, and some case studies published recently. The available data were immense, but we tried limiting the data to around 150 studies, from which the interlinked data have been gathered. Thus, after a thorough analysis of the dates, abstracts, titles, and journals of research publications, they were included in this review. Moreover, this review has mostly reviewed studies conducted after 2010, to elaborate on the latest therapeutic interventions and vaccines developed in the past decade. It should be noted that studies of English origin have been made part of the review.</p></sec></sec><sec id="s0025"><title>Results</title><sec id="s0030"><title>Chronic influenza infection and need for Therapies?</title><p id="p0625">There exist four categories of influenza viruses: A, B, C, and D. worldwide, nearly every winter, influenza A and B viruses lead to seasonal outbreaks of illness in humans, commonly referred to as the flu season <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>. Influenza A viruses stand as the exclusive culprits behind flu pandemics, marked by worldwide outbreaks of flu-related illnesses. A pandemic scenario unfolds when a novel and distinct influenza A virus emerges, capable of infecting humans, efficiently spreading among them, and encountering limited immunity <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>. On the other hand, Influenza C virus infections generally result in mild sickness and are not deemed responsible for widespread human outbreaks. In contrast, Influenza D viruses primarily impact cattle, occasionally spilling over to affect other animals, yet lacking the propensity to induce illness in humans <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>. Influenza mostly causes mild infection of the upper respiratory tract <xref rid="b0195" ref-type="bibr">[39]</xref>. However, in elderly or immune-compromised individuals can develop a severe infection and chronic cases in which the virus survives, especially in, where immunopathogenesis by influenza results in direct cellular damage in the airway epithelial layer coupled with tissue damage to the associated organs <xref rid="b0200" ref-type="bibr">[40]</xref>. During this period the influenza load peaks in the upper tract and peaks at the 3rd day causing fever and clinical symptoms. After 3rd-day the immune system mostly deals with the viral replication rates and viral loads and thus drops down <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>.</p><p id="p0630">This viral unloading, immune regulation, and controlled disease outcomes present an opportunity for scientists to design therapeutics to regulate the immune mechanism of action, especially to prevent cases of rapid disease progression and complications associated with chronic influenza infection <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0220" ref-type="bibr">[44]</xref>, <xref rid="b0225" ref-type="bibr">[45]</xref>. In most cases, treatment with different therapeutics is initiated before the virus takes a peak account within the body (24&#8211;36&#160;h) <xref rid="b0100" ref-type="bibr">[20]</xref>. The purpose is to strengthen the immune system and fight against influenza infection. Various disease management protocols and disease mitigation measures have indicated that a proactive response and rapid diagnosis and start of treatment are paramount to the therapeutic advantage against infection <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>. Thus, it will not be wrong to say that treatment-initiated time, body conditions, age, and immune system characteristics affect the treatment outcomes against Influenza infection <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref>, <xref rid="b0240" ref-type="bibr">[48]</xref>. Moreover, several recommendations have been suggested by the World Health Organization (WHO)to devise treatments for healthy people for the concerns of minimizing the viral resistance development <xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>. These guidelines suggest the use of antiviral medications, such as oseltamivir and zanamivir, for the treatment of confirmed or suspected cases of influenza. However, WHO emphasizes responsible usage to prevent the emergence of drug-resistant strains. These recommendations have been compiled in a figure format (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) in the following section. Some of the proposed trials and approved candidates of therapeutics against influenza are covered in the following sections and are presented in <xref rid="t0005" ref-type="table">Table 1</xref>.<xref rid="f0010" ref-type="fig">Fig. 2.</xref>.<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Recommendations to minimize the viral resistance development.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00005" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig><table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Summarizing therapeutics against influenzas virus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Sr. No.</bold></th><th colspan="1" rowspan="1">Therapeutic Strategies</th><th colspan="1" rowspan="1"><bold>Names Of Respective Antiviral Agents</bold></th><th colspan="1" rowspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">NA Inhibitors</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#9679;</label><p id="p0005">AdamantanesZanamivir</p><p id="p0010">(Relenza)Oseltamivir</p><p id="p0015">(Tamiflu)</p><p id="p0020">Peramivir</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0705" ref-type="bibr">[141]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Long-Acting NA Inhibitor</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0010"><list-item id="o0010"><label>&#9679;</label><p id="p0025">laninamivir (R-125489Laninamivir octanoate (CS-8958)</p><p id="p0030">prodrug</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">M2 Ion Channel Inhibitors</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0015"><list-item id="o0015"><label>&#9679;</label><p id="p0035">Amantadine (Symmetrel)Rimantadine</p><p id="p0040">(Flumadine)</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0395" ref-type="bibr">[79]</xref>, <xref rid="b0400" ref-type="bibr">[80]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Polymerase Inhibitors<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0020"><list-item id="o0020"><label>&#9679;</label><p id="p0045">Favipiravir (T-705)Pimodivir</p><p id="p0050">(VX-787)</p><p id="p0055">Combination of oseltamivir and T-705</p><p id="p0060">Ribavirin</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0710" ref-type="bibr">[142]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">HA Inhibitor</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0025"><list-item id="o0025"><label>&#9679;</label><p id="p0065">Cyanovirin-N (CV-N),</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Sialic Acid Receptor Inhibitor</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0030"><list-item id="o0030"><label>&#9679;</label><p id="p0070">DAS181 (Fludase&#174;)</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0255" ref-type="bibr">[51]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref>, <xref rid="b0350" ref-type="bibr">[70]</xref>, <xref rid="b0385" ref-type="bibr">[77]</xref>, <xref rid="b0390" ref-type="bibr">[78]</xref>, <xref rid="b0715" ref-type="bibr">[143]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">PA Endonuclease Inhibitors</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0035"><list-item id="o0035"><label>&#9679;</label><p id="p0075">Baloxavir&#160;Marboxil(PA I38T/M/F)</p><p id="p0080">model experiment</p><p id="p0085">EIDD-2801</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0385" ref-type="bibr">[77]</xref>, <xref rid="b0390" ref-type="bibr">[78]</xref>, <xref rid="b0715" ref-type="bibr">[143]</xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Neutralizing Antibodies (nAbs)<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0040"><list-item id="o0040"><label>&#9679;</label><p id="p0090">MHAA4548A,</p><p id="p0095">MEDI8852,</p><p id="p0100">VIS410</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0370" ref-type="bibr">[74]</xref>, <xref rid="b0380" ref-type="bibr">[76]</xref>, <xref rid="b0720" ref-type="bibr">[144]</xref>, <xref rid="b0725" ref-type="bibr">[145]</xref>, <xref rid="b0730" ref-type="bibr">[146]</xref>, <xref rid="b0735" ref-type="bibr">[147]</xref>, <xref rid="b0740" ref-type="bibr">[148]</xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Next-Generation Influenza Virus Inhibitor<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0045"><list-item id="o0045"><label>&#9679;</label><p id="p0105">Prodrug EIDD-2801, a 5&#8242;-isopropylester</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0385" ref-type="bibr">[77]</xref>, <xref rid="b0405" ref-type="bibr">[81]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0745" ref-type="bibr">[149]</xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Combination Therapy<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0050"><list-item id="o0050"><label>&#9679;</label><p id="p0110">Adamantanes (amantadine and rimantadine)&#160;+&#160;ribavirin.</p><p id="p0115">Rimantadine&#160;+&#160;NA inhibitor (zanamivir, oseltamivir carboxylate, or peramivir)Triple combination antiviral drug (TCAD) regimen</p><p id="p0120">(oseltamivir carboxylate, amantadine, and ribavirin)</p><p id="p0125">Peramivir&#160;+&#160;Ribavirin</p><p id="p0130">Rimantadine&#160;+&#160;Oseltamivir</p><p id="p0135">Oseltamivir&#160;+&#160;Ribavirin</p><p id="p0140">Oseltamivir&#160;+&#160;Amantadine Or Rimantadine</p><p id="p0145">Amantadine&#160;+&#160;Oseltamivir</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0225" ref-type="bibr">[45]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>, <xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0720" ref-type="bibr">[144]</xref>, <xref rid="b0750" ref-type="bibr">[150]</xref>, <xref rid="b0755" ref-type="bibr">[151]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0760" ref-type="bibr">[152]</xref>, <xref rid="b0765" ref-type="bibr">[153]</xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Other drug candidates<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0055"><list-item id="o0055"><label>&#9679;</label><p id="p0150">Systemic steroids and corticosteroids</p><p id="p0155">Drugs Statins</p><p id="p0160">Fibrates</p><p id="p0165">Thiozolidinediones</p><p id="p0170">Cyclooxygenase Pathway InhibitorsCorticosteroids</p><p id="p0175">(Anti-Inflammatory)</p><p id="p0180">Antioxidant- N-Acetyl-<sc>L</sc>-CysteineRosuvastatin</p><p id="p0185">(Cholesterol Biosynthesis)</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>, <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0360" ref-type="bibr">[72]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0745" ref-type="bibr">[149]</xref>, <xref rid="b0770" ref-type="bibr">[154]</xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">FDA approved drugs</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0060"><list-item id="o0060"><label>&#9679;</label><p id="p0190">Baloxavir marboxil</p><p id="p0195">Oseltamivir</p><p id="p0200">Peramivir</p><p id="p0205">Zanamivir</p><p id="p0210">Amantadine</p><p id="p0215">Rimantadine</p><p id="p0220">Favipiravir</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref>, <xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0445" ref-type="bibr">[89]</xref>, <xref rid="b0720" ref-type="bibr">[144]</xref>, <xref rid="b0750" ref-type="bibr">[150]</xref>, <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0775" ref-type="bibr">[155]</xref></td></tr></tbody></table></table-wrap><fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Limitations associated with NA Inhibitors therapies in complicated influenza cases.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00010" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec></sec><sec id="s0035"><title>Modern therapeutic strategies against chronic and seasonal influenzas</title><sec id="s0040"><title>Parenteral neuraminidase NA inhibitors and long-acting NA inhibitors</title><p id="p0635">NA inhibitors are the most widely used anti-influenza agents that inhibit the enzymatic activity of neuraminidases of Influenza A and Influenza B viruses (IAV) and (IBV) <xref rid="b0260" ref-type="bibr">[52]</xref>, preventing the cleavage in sialic acid residues on viral and host cell surfaces, blocking the virions binding on the host cell surface, resulting in virion replication cycle arrest <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>. Zanamivir (Relenza) and Oseltamivir (Tamiflu) are two of the antiviral medications used to treat and provide prophylaxis against influenza A and B. These drugs work&#160;by binding to neuraminidase, preventing the virus from escaping its host cell and infecting others.</p><p id="p0640">NAI has proven efficacy against influenza infections, but also has shown limitation against complicated and hospitalized cases <xref rid="b0275" ref-type="bibr">[55]</xref>. Addressing these limitations requires a multifaceted approach, including early diagnosis, judicious use of antiviral medications, potential combination therapy, and infection control measures to prevent further transmission. Some of the limitations have been described in figure-2. Resistance to NAI by numerous influenza strains is well documented and is an increasing problem The problem of rapid resistance development against NA proteins (H274Y, I223R, E119V, R292K, and N294S, Q136K) has been identified in NA inhibitors therapies that work against specific influenza subtypes such as H1N1, H5N1, and H3N2 subtypes <xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>.</p><p id="p0645">Some studies suggest that approximately 90&#160;% of strains of influenzas viruses developed resistance to these drugs during Pandemic times <xref rid="b0255" ref-type="bibr">[51]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>. To overcome this challenge a new class of NA inhibitors has been introduced during endemic 2009, known as Long-Acting NA Inhibitors, which prolong the retention of drugs in the lungs and requires lower drug dosages and greater efficacy compared to the previous class of NA inhibitor drugs <xref rid="b0275" ref-type="bibr">[55]</xref>. The designed drugs showed impact against common influenza viruses, viral subtypes N1-N9, and H1N1, H5N1 <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>.</p></sec><sec id="s0045"><title>RNA polymerase and polymerase&#160;complexes inhibitors</title><p id="p0650">These drugs work by inhibiting viral replication machinery during the early stages of the replication cycle by inhibition of RNA polymerase. The polymerases are incorporated into the newly synthesized viral RNA, resulting in transitioning mutation and collapse of the viral replication cycle <xref rid="b0300" ref-type="bibr">[60]</xref>. These antiviral drugs have shown efficacy against various types of influenza viruses, including influenza species A (subtypes: H1N1, H2N2, and H3N2), B, and C and oseltamivir-resistant viruses <xref rid="b0300" ref-type="bibr">[60]</xref>, <xref rid="b0305" ref-type="bibr">[61]</xref>. A dose-dependent application of these drugs has been checked to reduce virus titers to event fatality and to inhibit lung consolidation, thus, presenting a chance to overcome the resistant nature of the influenza virus and reduce modalities associated with hospitalized cases <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>. Notably, a similar mechanism of action has been proposed for other viruses such as arenavirus,&#160;bunyavirus, flavivirus,&#160;norovirus,&#160;picornavirus, alphavirus, paramyxovirus, and&#160;rhabdovirus&#160;families <xref rid="b0320" ref-type="bibr">[64]</xref>, <xref rid="b0325" ref-type="bibr">[65]</xref>. Similar to the polymerase inhibitor mechanism, some antiviral agents are being designed against RNA-dependent RNA&#160;polymerase&#160;(Rd<underline>RP)</underline> complexes of infectious viruses. These are small-scale molecular therapeutics that are radially tested in clinical trials for their associated efficacy. The replication strategy associated with RdRP organization and polymerase complex is majorly conserved among subtypes of IAVs and IBVs, which increases the likelihood of the development of a broad-spectrum anti-therapeutic approach against different influenza species <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>.</p></sec><sec id="s0050"><title>HA Inhibitors</title><p id="p0655">HA inhibitors function by binding to the glycoproteins of enveloped viruses, undergoing structural changes, and inhibiting viral entry into the host cell <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref>. Moreover, the mutational problem associated with glycosylation sites of HA further reduces the antiviral activities. Since the specific strains of influenza viruses can change from season to season due to antigenic drift (minor genetic changes), and occasionally antigenic shift (major genetic changes), therefore, more work is needed to prove their anti-viral efficacy against a diverse range of influenza species and to establish modified versions of HA inhibitors against mutated regions <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0340" ref-type="bibr">[68]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>.</p></sec><sec id="s0055"><title>Sialic acid receptor inhibitors</title><p id="p0660">This drug inhibits the host cell components necessary for viral replication and reduce the drug resistance variants among influenza viruses in the host <xref rid="b0335" ref-type="bibr">[67]</xref>. Receptors containing sialic acid (SA) are present in susceptible host cells essential for the binding of HA viral proteins with host receptor cells <xref rid="b0255" ref-type="bibr">[51]</xref>. These antiviral agents avert infection from influenza A (H1N1, H5N1), B virus subtypes, and NA inhibitor-resistant influenzas species, and parainfluenza viruses<xref rid="b0255" ref-type="bibr">[51]</xref>, <xref rid="b0335" ref-type="bibr">[67]</xref>, <xref rid="b0350" ref-type="bibr">[70]</xref>. Although the cytotoxicity profile of Sialic Acid Receptor Inhibitors are well established, its resistive profile needs to be further established in human subjects <xref rid="b0255" ref-type="bibr">[51]</xref>.</p></sec><sec id="s0060"><title>Neutralizing antibodies (nAbs)</title><p id="p0665">Antibodies-based therapy have shown high tolerability and enhanced pharmacokinetic against influenza infections <xref rid="b0355" ref-type="bibr">[71]</xref>, just like neutralizing antibodies treatment against different viral infections such as Ebola, RSV, HIV, Dengue, and others. In the case of an influenza virus, the nAbs function against the highly immunogenic receptor binding sites (RBCs) across different subtypes of the influenza virus of the virus <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0360" ref-type="bibr">[72]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>. Neutralizing antibodies accelerate the resolution of disease severity and reduce viral load in the tested models. Moreover, an essential feature is their long shelf life and reduced dosage needs, with no reported resistance reported yet <xref rid="b0370" ref-type="bibr">[74]</xref>, <xref rid="b0375" ref-type="bibr">[75]</xref>. Some novel research is coming forward that includes the use of multidomain antibodies against different types of influenza viruses <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0370" ref-type="bibr">[74]</xref>, but need further assessment against cross-resistance and cost-benefit analyses, as these therapies are still in research phase 2 <xref rid="b0370" ref-type="bibr">[74]</xref>, <xref rid="b0380" ref-type="bibr">[76]</xref>.</p></sec><sec id="s0065"><title>PA endonuclease inhibitors</title><p id="p0670">These inhibitor drugs are a new class of anti-influenza agents that blocking the PA endonuclease activity, necessary for viral infectious cycle regulation <xref rid="b0315" ref-type="bibr">[63]</xref>. Their efficacy is similar to standard therapy approaches with NAIs but presents better dose efficacy compared to NAIs <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>, <xref rid="b0385" ref-type="bibr">[77]</xref>, <xref rid="b0390" ref-type="bibr">[78]</xref>. Moreover, the drugs in this category, specifically baloxavir&#160;marboxil has shown antiviral activity against various subtypes of influenza virus, including A, B, C, and G generas, making them a wide spectrum of therapeutics against influenza infection [<xref rid="b0330" ref-type="bibr">[66]</xref>. There are some minor side effects associated with the drugs, such as headache, increased white blood cell count <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>. Nevertheless, resistance has also been observed in some patients against baloxavir marboxil, with a rebound viral load and the prolonged manifestation of clinical symptoms associated with patients&#8217; profiles <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>.</p></sec><sec id="s0070"><title>M2 ion channel inhibitors</title><p id="p0675">These antiviral agents function by inhibiting the replication cycle at two different steps of viral replication. These drugs block the ion channel activity of M2 proteins of IAVs, which is necessary for virus entry and uncoating within the host cell as well as inhibit activity at the later stages of replication, preventing the release of virion replicons from the infected host cells [<xref rid="b0395" ref-type="bibr">[79]</xref>, <xref rid="b0400" ref-type="bibr">[80]</xref>. Moreover, this replication occurs in a strain-specific manner.</p></sec><sec id="s0075"><title>Next-generation influenza virus inhibitors</title><p id="p0680">These antiviral agents use a novel approach that involve efficient anabolism of the bioactive tri-phosphate component, followed by incorporation as cytisine into the viral RNA with the help of polymerase action <xref rid="b0250" ref-type="bibr">[50]</xref>. This is followed by high rates of transition mutation in viral RNA polymerase and other transcription products resulting errors in replication cycle and lower viral loads in tissue cultures [<xref rid="b0405" ref-type="bibr">[81]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>. These antiviral strategies have been checked against other infectious viruses belonging to the alphavirus,&#160;coronavirus, flavivirus, and&#160;togavirus&#160;families, making them a possible candidate for broad-spectrum antiviral agents. However, to establish their safety profiles these antiviral candidates further clinical experiments on are needed <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref>, <xref rid="b0385" ref-type="bibr">[77]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>.</p></sec><sec id="s0080"><title>Other potential drug agents in clinical trials</title><p id="p0685">With the advancement in our understanding about influenza virus life cycle, replication machinery, mechanism of action toward disease development and the respective immune response from host cells new drug candidates come to the surface, such as small interfering RNAs (siRNAs) and micro RNAs (miRs) that could be designed to target viral RNA without affecting host RNA <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0410" ref-type="bibr">[82]</xref>. These RNAs based technology has already shown its targeted efficiency in various diseases in terms of high specificity, efficiency, low toxicity, and ease of formulation <xref rid="b0415" ref-type="bibr">[83]</xref>, <xref rid="b0420" ref-type="bibr">[84]</xref>. A diverse range of in silico experiments are in research annals for RNA-based inhibitor therapies against influenza virus infection, the need is to dictate these proposed candidates into clinical trials <xref rid="b0425" ref-type="bibr">[85]</xref>, <xref rid="b0430" ref-type="bibr">[86]</xref>.</p><p id="p0690">Similarly, immune therapies are introduced in the market against several infectious viral diseases such as neutralizing antibodies <italic toggle="yes">(nAbs)</italic> against influenza viruses (as discussed above). These antibody-based therapies may include intravenous immune globulin (IVIG) (simple terms antibodies), hyperactive immune sera from vaccinated individuals, and mixtures of monoclonal antibodies for therapies <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0370" ref-type="bibr">[74]</xref>. These immunomodulatory therapies broadly work to neutralize viral infection by reducing the inflammatory response and activating the immune systems against viruses&#8217; entrance <xref rid="b0370" ref-type="bibr">[74]</xref>, <xref rid="b0375" ref-type="bibr">[75]</xref>. Additionally, different chemical, hormones, and enzymatic preparations have also been studied in different clinical experiments, some of which have been made part of <xref rid="t0005" ref-type="table">Table 1</xref>, but further clinical experiments on are needed.</p></sec></sec><sec id="s0085"><title>Current influenza vaccines</title><p id="p0695">The ever-evolving nature of the Influenza virus makes it pertinent to design a permanent therapeutic solution <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0410" ref-type="bibr">[82]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>. The mutations are exhibited in the various virus proteins such as surface glycoproteins HA, NA, or nucleoproteins <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0435" ref-type="bibr">[87]</xref>, <xref rid="b0440" ref-type="bibr">[88]</xref>, <xref rid="b0445" ref-type="bibr">[89]</xref>, resulting in generation of new viral strains. Antigenic shift occurs when there is a reassortment of genetic segments between different virus strains. Typically, it is a transfer from animal (i.e. swine) into human strains. Pandemic strains emerge as a consequence of antigenic shift because it presents a new virus to a naive immune system.</p><p id="p0700">Additionally, the point mutations result in major antigenic shifts and heterogeneity in virus strains and thus make it difficult to formulate a one-time solution against it <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0445" ref-type="bibr">[89]</xref>. The various pandemics and epidemics of the past such as those caused by (H1N1-First human case in 1918, 2009; H2N2-1957; 1968-H3N2; H5N1: 1997; H7N9:2013) subtypes, presented a public healthcare threat worldwide <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0450" ref-type="bibr">[90]</xref>. While Limited human cases reported, with no specific pandemic identified for H7N2, H7N3, H7N7 and H9N2. Several vaccines have been developed against influenzas virus and some of the latest vaccination approaches with established efficacious profiles are discussed below (see <xref rid="t0010" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Vaccination strategies against influenza virus.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><bold>Sr. No.</bold></th><th colspan="1" rowspan="1"><bold>Vaccines Category</bold></th><th colspan="1" rowspan="1"><bold>Vaccine Candidates Under Clinical Trials</bold></th><th colspan="1" rowspan="1"><bold>Reference</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">HA protein-based vaccine</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0065"><list-item id="o0065"><label>&#9679;</label><p id="p0225">HA Rosettes,</p><p id="p0230">HA nanoparticles,</p><p id="p0235">VLP&#160;+&#160;Matrix-MTM adjuvant</p><p id="p0240">HA stem or head-stem chimeraFlu Blok</p><p id="p0245">(recombinant)</p><p id="p0250">Monoglycosylated HA- a universal flu vaccine candidate, with conserved domain</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0455" ref-type="bibr">[91]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Epitope-peptides based vaccine<break/>(NA or HA based vaccines)</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0070"><list-item id="o0070"><label>&#9679;</label><p id="p0255">HA, NP, M1 peptides</p><p id="p0260">FLU-V</p><p id="p0265">MVA-vectored NP&#160;+&#160;M1 vaccine</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0255" ref-type="bibr">[51]</xref>, <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0485" ref-type="bibr">[97]</xref>, <xref rid="b0490" ref-type="bibr">[98]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0780" ref-type="bibr">[156]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Live attenuated virus vaccine</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0075"><list-item id="o0075"><label>&#9679;</label><p id="p0270">CodaVaxFluMist</p><p id="p0275">(AstraZeneca)</p><p id="p0280">M2SRFluenz Tetra</p><p id="p0285">(licensed)M2-deficient single replication virus</p><p id="p0290">(targeting B cells)</p><p id="p0295">Approved vaccines</p><p id="p0300">A/Len/134/17/57,</p><p id="p0305">A/Len/134/47/57,</p><p id="p0310">B/USSR/60/69,</p><p id="p0315">A/Ann Arbor/6/60,</p><p id="p0320">B/Ann Arbor/1/66</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0545" ref-type="bibr">[109]</xref>, <xref rid="b0550" ref-type="bibr">[110]</xref>, <xref rid="b0555" ref-type="bibr">[111]</xref>, <xref rid="b0785" ref-type="bibr">[157]</xref>, <xref rid="b0790" ref-type="bibr">[158]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Nucleic acid-based vaccine</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0080"><list-item id="o0080"><label>&#9679;</label><p id="p0325">Vaccines candidates belonging to DNA and Mrna targeting HA Nabs</p><p id="p0330">DNA based- mucosal influenza vaccines &#8211; FluMist</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0545" ref-type="bibr">[109]</xref>, <xref rid="b0610" ref-type="bibr">[122]</xref>, <xref rid="b0615" ref-type="bibr">[123]</xref>, <xref rid="b0620" ref-type="bibr">[124]</xref>, <xref rid="b0795" ref-type="bibr">[159]</xref>, <xref rid="b0800" ref-type="bibr">[160]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Virus like particles-based vaccines (recombinant technology)</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0085"><list-item id="o0085"><label>&#9679;</label><p id="p0335">M2e5x VLP vaccinesM2 VLP-supplemented inactivated influenza virus vaccine</p><p id="p0340">(A/PR/8/34, H1N1)H1N1 split vaccine</p><p id="p0345">(A/California/07/2009)&#160;+&#160;M2e5x VLPsrecombinant vaccine candidate-M2e-HBc fusion protein</p><p id="p0350">(ACAM-FLU-A)M2e-flagellin fusion vaccine</p><p id="p0355">(STF2.4xM2e)Ferritin-based NPs&#8211;HA</p><p id="p0360">(targeting HA Nabs)VLP&#8211;HA; NA; M1; M2</p><p id="p0365">(targeting HA NAbs; T cells)Peptide&#8211;HA, NP, M1</p><p id="p0370">(targeting T cells; B cells)Peptide&#8211;NP; M1; M2</p><p id="p0375">(targeting T cells)</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0565" ref-type="bibr">[113]</xref>, <xref rid="b0575" ref-type="bibr">[115]</xref>, <xref rid="b0590" ref-type="bibr">[118]</xref>, <xref rid="b0805" ref-type="bibr">[161]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Vector based vaccines</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0090"><list-item id="o0090"><label>&#9679;</label><p id="p0380">Alphavirus- (targeting HA Nabs)Adenovirus-</p><p id="p0385">(targeting HA Nabs)</p><p id="p0390">Chimpanzee adenovirus&#8211;NP&#160;+&#160;M2 (targeting T cells)</p><p id="p0395">Modified vaccinia virus Ankara&#8211;HA NP&#160;+&#160;M1 (targeting HA NAbs; T cells)</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0660" ref-type="bibr">[132]</xref>, <xref rid="b0740" ref-type="bibr">[148]</xref>, <xref rid="b0810" ref-type="bibr">[162]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">M2-based protein vaccine</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0095"><list-item id="o0095"><label>&#9679;</label><p id="p0400">M2e&#160;+&#160;HBVc VLPs</p><p id="p0405">Recombinant M2e-GCN4 conjugate vaccine</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0395" ref-type="bibr">[79]</xref>, <xref rid="b0400" ref-type="bibr">[80]</xref>, <xref rid="b0570" ref-type="bibr">[114]</xref>, <xref rid="b0810" ref-type="bibr">[162]</xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Inactivated split virus vaccines<break/>(Targeting HAI and licensed)<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0100"><list-item id="o0100"><label>&#9679;</label><p id="p0410">Afluria Fluarix</p><p id="p0415">FluLavel</p><p id="p0420">Fluzone, Fluzone HD</p><p id="p0425">Fluad</p><p id="p0430">Influvac, Imuvac</p><p id="p0435">Fluarix, Alpharix, Influsplit</p><p id="p0440">3Fluart</p><p id="p0445">Afluria, Enzira</p><p id="p0450">Vaxigrip, Vaxigrip Tetra</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0540" ref-type="bibr">[108]</xref>, <xref rid="b0570" ref-type="bibr">[114]</xref>, <xref rid="b0740" ref-type="bibr">[148]</xref>, <xref rid="b0815" ref-type="bibr">[163]</xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Inactivated Subunit vaccines (Targeting HAI and licensed)</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0105"><list-item id="o0105"><label>&#9679;</label><p id="p0455">Fluvirin</p><p id="p0460">Flucelvax</p><p id="p0465">Agrippal Fluad</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0570" ref-type="bibr">[114]</xref>, <xref rid="b0740" ref-type="bibr">[148]</xref>, <xref rid="b0815" ref-type="bibr">[163]</xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">T cell-based vaccines</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0110"><list-item id="o0110"><label>&#9679;</label><p id="p0470">(MVA-NP&#160;+&#160;M1)</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0200" ref-type="bibr">[40]</xref>, <xref rid="b0595" ref-type="bibr">[119]</xref>, <xref rid="b0600" ref-type="bibr">[120]</xref>, <xref rid="b0745" ref-type="bibr">[149]</xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Trivalent and Quadrivalent vaccines<break/></td><td colspan="1" rowspan="1"><list list-type="simple" id="l0115"><list-item id="o0115"><label>&#9679;</label><p id="p0475">MedImmune's nasal spray vaccine,</p><p id="p0480">FluMist quadrivalent</p><p id="p0485">injectable quadrivalent influenza vaccine.</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0560" ref-type="bibr">[112]</xref>, <xref rid="b0820" ref-type="bibr">[164]</xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">Adjuvants for influenza vaccination</td><td colspan="1" rowspan="1"><list list-type="simple" id="l0120"><list-item id="o0120"><label>&#9679;</label><p id="p0490">Alum,</p><p id="p0495">MF59,</p><p id="p0500">AS03 and AF03,</p><p id="p0505">saponins,Toll-like receptor&#160;(TLR)</p><p id="p0510">agonists such as TLR4, TLR5, TLR7/8 and TLR9,</p><p id="p0515">Polysaccharides and glycolipids, lipopeptides, glycolipids,</p><p id="p0520">Nucleotides, small-molecule inhibitors</p><p id="p0525">Bacterial-derived components, such as flagellin</p><p id="p0530">
<bold>Natural compounds drved adjuvants</bold>
</p><p id="p0535">QS21, is a saponin-based adjuvant.Extract from&#160;<italic toggle="yes">Panax ginseng</italic>.</p><p id="p0540">Alpha-galactosyl ceramide (alpha-GalCer), an extract from marine sponge.</p><p id="p0545">
<bold>Cytokine adjuvants- inflammatory mediator</bold>
</p><p id="p0550">IL-6,</p><p id="p0555">GM-CSF</p><p id="p0560">
<bold>Synthetic nanocarriers and Cationic lipids (liposomes)</bold>
</p><p id="p0565">Vaxfectin -cationic lipid-based systemPoly(lactic-co-glycolic)</p><p id="p0570">acid,</p><p id="p0575">Chitosan,</p><p id="p0580">Polyethyleneimine.</p></list-item></list></td><td colspan="1" rowspan="1"><xref rid="b0525" ref-type="bibr">[105]</xref>, <xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0660" ref-type="bibr">[132]</xref>, <xref rid="b0665" ref-type="bibr">[133]</xref>, <xref rid="b0670" ref-type="bibr">[134]</xref>, <xref rid="b0800" ref-type="bibr">[160]</xref>, <xref rid="b0825" ref-type="bibr">[165]</xref>, <xref rid="b0830" ref-type="bibr">[166]</xref></td></tr></tbody></table></table-wrap></p><sec id="s0090"><title>Ha-based vaccines against influenza</title><p id="p0705">HA is the type I transmembrane glycoprotein (surface glycoprotein) that presents a major fraction of enveloped viral proteins and help viral attachment and cellular entry <xref rid="b0455" ref-type="bibr">[91]</xref>. In case of influenza infection or vaccine regimens it acts as antigens and help mediate the immune responses <xref rid="b0460" ref-type="bibr">[92]</xref>. Neutralizing antibodies are produced that avert the viral entry and receptor-mediated endocytosis of the Influenza virus. The principle is in use for a long for traditional vaccine designs and differential characteristics are assigned to vaccine formulation by varying the antigenic HA components within vaccines <xref rid="b0465" ref-type="bibr">[93]</xref>, <xref rid="b0470" ref-type="bibr">[94]</xref>, <xref rid="b0475" ref-type="bibr">[95]</xref>. Moreover, with the enhanced structural understanding of HA and other enveloped proteins through bioinformatics, biophysics, and biochemistry tools, better vaccine formulations are on board for the future <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0480" ref-type="bibr">[96]</xref>. However, there remains the hurdle of virus strain-specific mutational alterations that render the HA-based vaccine ineffective against a broad range of viruses <xref rid="b0455" ref-type="bibr">[91]</xref>. Several clinical trials based upon HA-based vaccination approaches have been conducted in recent years, some of which have been made part of table 2 <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>.</p></sec><sec id="s0095"><title>Neuraminidase NA-Based vaccines</title><p id="p0710">Neuraminidase, another influenza-enveloped protein that has remained in vaccination practices and have shown better immunoregulatory activity as compared to standard HA-vaccine <xref rid="b0485" ref-type="bibr">[97]</xref>. NA is a type II transmembrane glycoprotein with further 11 subtypes divided into three genetic groups <xref rid="b0260" ref-type="bibr">[52]</xref>. Like HA antigens, antibodies against NA have also been identified but their exact role in immune regulation remains elusive <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>. Therapeutics and antiviral agents such as oseltamivir, zanamivir, and lopinavir have been designed to inhibit NA and the same principle is under investigation for vaccine designing <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0440" ref-type="bibr">[88]</xref>, <xref rid="b0490" ref-type="bibr">[98]</xref>. Additionally, the research show that NA and HA mutation, and genetic diversity are irrespective of each other, and the confluence results in a lesser severity of viral mutation and better chances for therapeutic management against influenza <xref rid="b0490" ref-type="bibr">[98]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>. Thus, several NA-based vaccine trials are under consideration (<xref rid="t0010" ref-type="table">Table 2</xref>).</p></sec><sec id="s0100"><title>Matrix protein 2 ectodomain-based vaccines</title><p id="p0715">Matrix protein 2 ectodomains (M2e) is an important proteinaceous entity, which is a pH-dependent and proton-selective ion channel protein <xref rid="b0495" ref-type="bibr">[99]</xref>. The proteins function to help the virus disassemble, and release of virus core and subsequent viral budding and release and thus are conserved in influenza viruses <xref rid="b0495" ref-type="bibr">[99]</xref>, <xref rid="b0500" ref-type="bibr">[100]</xref>. However, it has shown lesser immunogenicity when exposed to a cellular environment. However, experiments based on additional adjuvants and combination therapies show that these particles could be utilized for broad-range immunity generation in animal models <xref rid="b0505" ref-type="bibr">[101]</xref>. Although the quantification of M2e base vaccination regiments will remain a limitation when a universal vaccine candidate will be designed since it could only passively create monoclonal antibodies and decrease overall viral load in influenza incidences <xref rid="b0510" ref-type="bibr">[102]</xref>. Some antiviral therapies such as amantadine and rimantadine against influenza infection are also based on inhibiting activity against M2 protein <xref rid="b0515" ref-type="bibr">[103]</xref>, <xref rid="b0520" ref-type="bibr">[104]</xref>. Formulation of a broad spectrum and largely immunoregulatory vaccine by conjugating the M2e-based vaccine with HA-based vaccination, is going on.</p></sec><sec id="s0105"><title>Nucleoprotein-based vaccines</title><p id="p0720">NP is an internal influenza virus protein that serves as a target for generating T cell-based immune responses and thus is under various ongoing trials <xref rid="b0525" ref-type="bibr">[105]</xref>. T cell-based responses cause stimulation of intraepithelial tissue-resident memory immune responses <xref rid="b0515" ref-type="bibr">[103]</xref>, <xref rid="b0530" ref-type="bibr">[106]</xref>, <xref rid="b0535" ref-type="bibr">[107]</xref>. It holds the ability to generate durability, potency, and a wide breadth of immunity against influenza infection. Moreover, NP-based therapies have also exhibited the characteristic of heterosubtypic immunity regulation against influenza subtypes. T-cell-based immunity regulates direct cytotoxicity induced by CD-8 cell-mediated responses and generates B-cell responses in the form of an immune system interconnected response when exposed to influenza particles <xref rid="b0505" ref-type="bibr">[101]</xref>, <xref rid="b0525" ref-type="bibr">[105]</xref>. Persons that undergo NP-based vaccination have shown lower symptoms of influenza as compared to unvaccinated. The need is to further carry out experiments in this domain to establish a universal vaccine.</p></sec><sec id="s0110"><title>Conventional inactivated influenza vaccines</title><p id="p0725">In this approach, chemically or radiationally inactivated virus particles are used which are unable to further divide when introduced into host cells, but cause antibodies-based immune responses <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0540" ref-type="bibr">[108]</xref>. The mechanism was used for the first vaccine trials that involved a whole inactivated virus particle for both influenza A and B subtypes <xref rid="b0175" ref-type="bibr">[35]</xref>. One of the currently used conventional vaccine candidates is a trivalent vaccine that contains B-type influenza variants and two of influenzas A variants (H1N1 and H3N2) <xref rid="b0185" ref-type="bibr">[37]</xref>. They work on the same principle as the HA and NA-based vaccine protocol. Due to their highly efficacious nature, they are in practice since 1970. A limiting feature of these vaccines is their variable efficacy, short immune-protective regulation, and low capacity to induce cellular immunity <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0540" ref-type="bibr">[108]</xref>. Thus, efforts should be diverted to conjugate these vaccines with other vaccine formulations and adjuvants for better treatment response.</p></sec><sec id="s0115"><title>Live attenuated virus (LAIV) vaccines</title><p id="p0730">To deal with the variable efficacy of inactivated vaccines, another traditional approach of using live virus particles has been in practice. These vaccines are designed with the feature of internal proteins from a master donor virus and surface glycoproteins from wild-type influenza <xref rid="b0545" ref-type="bibr">[109]</xref>, <xref rid="b0550" ref-type="bibr">[110]</xref>. They have shown better vaccination outcomes, especially in children as compared to inactive vaccine candidates, thus could be utilized against all children and adults below age of 50&#160;years, and those with respiratory problems. Moreover, they induce humoral and cellular antibody-based immunity and Potential Herd Immunity in case of vaccination against a significant population of patients <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0555" ref-type="bibr">[111]</xref>. Some clinical outcomes linked with LAIV vaccines against influenza virus disease are compiled in the <xref rid="f0015" ref-type="fig">Fig. 3</xref> below.<fig id="f0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Clinical Outcomes Linked with LAIV Vaccines Against Influenza Virus Disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00015" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p></sec><sec id="s0120"><title>Trivalent and quadrivalent influenza vaccines</title><p id="p0735">As elaborated earlier vaccine designs such as trivalent and quadrivalent are designed to curtail the wide spectrum of influenza infection. Quadrivalent vaccine design incorporates four strains, two from influenza A subtype (H1N1, H3N2) and two from type B strains (Victoria, Yamagata) <xref rid="b0185" ref-type="bibr">[37]</xref>. These vaccination designs are useful since the virus keeps on mutating and generating different strains. Thus, multiple trivalent and quadrivalent vaccine trials are under clinical experimental design phase. In case of trivalent inactivated vaccine candidates, three vaccine subtypes conjugates: spilled, subunit, and whole virus vaccines are used <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>. They are often used together to induce more specific and highly immunogenic responses. In the case of split vaccines, the virus is rendered inactive, in the subunit, the HA or NA antigens are used <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0560" ref-type="bibr">[112]</xref>. Moreover, these vaccines involve conjugation with adjuvants.</p><p id="p0740">Trivalent influenza vaccines typically contain three strains of influenza virus: two subtypes of influenza A and one influenza B strain. The composition of these strains is determined based on predictions about the most likely circulating flu viruses for the upcoming flu season. The specific strains can vary from year to year. The trivalent vaccine includes antigens from: Influenza A (H1N1), Influenza A (H3N2), Influenza B. However as mentioned earlier WHO is now recommending removal of the influenza B (Yamagata lineage) from such formulations. These vaccines aim to provide protection against the selected strains and help prevent influenza infection. It's worth noting that there are also quadrivalent influenza vaccines that include an additional influenza B strain. WHO determines the vaccine strains to be included in each flu season's vaccine twice a year (once prior to the Northern Hemisphere's flu season and once prior to the Southern Hemisphere's flu season).</p></sec><sec id="s0125"><title>Conjugated recombinant vaccination protocols</title><p id="p0745">Virus entities such as glycoproteins and nucleoproteins or the M2e ion proteins independently are not efficient enough to generate broad-scale immunogenicity and only generate mild passive-type immunological responses by lowering the viral progenies alone in hosts <xref rid="b0285" ref-type="bibr">[57]</xref>. Therefore, the need is to conjugate these available protocols with adjuvants (discussed below) or with other viral entities to generate a strong immune protective response for controlling influenza epidemics and pandemics <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0565" ref-type="bibr">[113]</xref>. Several approaches are under consideration to induce a multi-carrier or multi-adjuvant conjugation with virus-targeted peptides. In these trials, the lower immunogenic molecules such as M2e proteins are conjugated with virus carrier molecules that may be derived from other viruses such as hepatitis B virus or human papillomavirus proteins, bacterial membrane structure, or artificially manufactured liposomes <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0570" ref-type="bibr">[114]</xref>. Some vaccine candidates such as recombinant M2e carrier vaccines have demonstrated excellent immune protective effects against different influenza strains such as H1N1, H3N2, and H5N1 <xref rid="b0570" ref-type="bibr">[114]</xref>. However, these conjugated protocols based on M2e conjugates still show lower immunity as compared to NA or HA- based vaccination mediated immune protection.</p></sec><sec id="s0130"><title>VLP vaccines</title><p id="p0750">Conjugation of M2e protein in enveloped VLPs that normally express either HA or NA or both and hence demonstrate excellent immunogenic profiles <xref rid="b0575" ref-type="bibr">[115]</xref>. These VLP-based vaccines have exhibited better immune responses than whole inactivated virus particles since they lack the shielding impact of large proteins <xref rid="b0580" ref-type="bibr">[116]</xref>, <xref rid="b0585" ref-type="bibr">[117]</xref>. VLP-based vaccines have shown efficacy against diverse subtypes of influenza including H1N1, H3N2, and H5N1, but suffer from silent amino acid variations in different host species <xref rid="b0590" ref-type="bibr">[118]</xref>. To overcome this challenge and to improve the vaccine efficacy tandem repeats of M2e epitope sequences for different species have been incorporated into vaccine, which have exhibited better immunogenic profiles and have exhibited cross-protection against virus subtypes even with limited or no adjuvants <xref rid="b0575" ref-type="bibr">[115]</xref>, <xref rid="b0590" ref-type="bibr">[118]</xref>. However, these viral candidates require further molecular insights and proper vaccination designs involving conjugation with other vaccines, antiviral, and adjuvants to develop an effective broad-spectrum influenza vaccine.</p></sec><sec id="s0135"><title>T cell-based vaccines</title><p id="p0755">Continuous mutation at antigenic sites including HA, NA, and other surface molecules generate influenza variants, which escape the neutralizing antibody response <xref rid="b0595" ref-type="bibr">[119]</xref>. However, cytotoxic T lymphocytes (CTLs) can recognize the conserved viral structures such NP and PA or the M2e and matrix 1 protein (M1), generating immunity against different influenza subtypes <xref rid="b0600" ref-type="bibr">[120]</xref>, <xref rid="b0605" ref-type="bibr">[121]</xref>. This mechanism is used for designing different vaccines such as live attenuated, plasmid or DNA vaccines, virus-like articles, and viral vector-based vaccines. These vaccines not only mediate T cell-mediated cytotoxicity against influenza, but also mediate B cell and humoral immune responses against influenza.</p></sec><sec id="s0140"><title>DNA vaccine</title><p id="p0760">In this vaccination protocol, naked plasmids are injected into the host to produce the specific antigens and subsequent antibody-mediated responses. Depending upon the dosages and conjugated adjuvant applications the DNA vaccines could be regulated for their immunogenicity potential <xref rid="b0610" ref-type="bibr">[122]</xref>. The route of administration plays a critical role in such vaccination protocols. More specifically cutaneous delivery has been largely practiced for its linked benefits of immune cells being abundant in the epidermis, which sufficiently transports the DNA-based vaccine antigens to particular immune cells in lymph nodes <xref rid="b0615" ref-type="bibr">[123]</xref>, <xref rid="b0620" ref-type="bibr">[124]</xref>.</p></sec><sec id="s0145"><title>Prime-boost strategies</title><p id="p0765">Like conjugated and recombinant vaccine protocols, prime-boost strategies are used to infer broad-scale immunity. Such as the co-administration of novel vaccine candidates including virus-like particles, and recombinant protein antigens through an adenovector platform altogether with the conventional vaccine candidate <xref rid="b0625" ref-type="bibr">[125]</xref>. This priming strategy boosts the serological presence and antibody-based cross-reactivity and immune boosting response <xref rid="b0630" ref-type="bibr">[126]</xref>. The prime-boost strategy in influenza vaccination involves initially priming the immune system with one formulation of the vaccine, followed by a subsequent booster dose containing a different formulation <xref rid="b0625" ref-type="bibr">[125]</xref>. For example in Priming Inoculation the initial vaccine includes antigens from specific influenza strains which is followed by the Boosting Inoculation through The booster dose, administered weeks later, contains antigens from influenza strains of different virus strains. The specific timing between the priming and boosting doses may vary, but it's typically designed to allow the immune system to develop a memory response after the priming dose, and the booster serves to enhance and prolong that immune response <xref rid="b0630" ref-type="bibr">[126]</xref>. The reason behind introducing different strains in the priming and boosting doses, is that the immune system is exposed to a broader range of influenza antigens. This helps create a more diverse and robust immune response <xref rid="b0635" ref-type="bibr">[127]</xref>. Additionally, the priming dose stimulates the production of memory B and T cells specific to the initial strains. The booster dose then activates these memory cells, leading to a faster and more effective immune response upon subsequent exposure to the virus. Moreover,&#160;the prime-boost strategy aims to improve overall vaccine efficacy by addressing the challenge of influenza virus variability <xref rid="b0640" ref-type="bibr">[128]</xref>. Since Influenza viruses undergo frequent genetic changes, and a prime-boost approach helps enhance protection against a wider spectrum of evolving strains. The booster dose also reinforces and extends the duration of immunity, providing a more prolonged defense against influenza viruses. This strategy is particularly important in the context of influenza, where the virus can undergo frequent antigenic changes, necessitating periodic updates to the vaccine formulations. The prime-boost strategy helps maximize the breadth and durability of the immune response, contributing to more effective protection against diverse influenza strains <xref rid="b0645" ref-type="bibr">[129]</xref>.</p><p id="p0770">The experiments with the primary HA-based DNA vaccines conjugated with the application of season trivalent inactive vaccines have been shown to significantly boost antibody-mediated immune titers <xref rid="b0635" ref-type="bibr">[127]</xref>, <xref rid="b0640" ref-type="bibr">[128]</xref>. Moreover, these prime-boost strategies are recommended for pandemic incidences to curb the rapid surge of virus infections in the populace <xref rid="b0635" ref-type="bibr">[127]</xref>. This implication was practiced during the 2009 pandemic in which phase 1 clinical trials were conducted using A(H1N1) <xref rid="b0635" ref-type="bibr">[127]</xref>, <xref rid="b0640" ref-type="bibr">[128]</xref>, <xref rid="b0645" ref-type="bibr">[129]</xref>. Similarly, DNA prime-MIV boost vaccines against H5N1 and H7N9 also demonstrated improved antibody responses compared to the same vaccines when used alone <xref rid="b0440" ref-type="bibr">[88]</xref>, <xref rid="b0645" ref-type="bibr">[129]</xref>, <xref rid="b0650" ref-type="bibr">[130]</xref>.</p></sec><sec id="s0150"><title>Vaccine adjuvants</title><p id="p0775">Adjuvants act as immunostimulatory agents that help to enhance immunogenicity by promoting innate immunity and inducing humoral or adaptive immune responses when administered along with drugs or vaccine formulations <xref rid="b0655" ref-type="bibr">[131]</xref>. In addition to immunoregulatory effects, they also add to dose management, desirable responses, and increased memory immune responses in a population that undergoes poor responses upon vaccine such as immunocompromised individuals like the elderly, pregnant women, and children <xref rid="b0660" ref-type="bibr">[132]</xref>. Moreover, they show immunogenicity against both season and pandemic species of influenza virus and their pharmaceutical, cytotoxic and tolerance profiles are well established for application against influenza and other related virus infections <xref rid="b0660" ref-type="bibr">[132]</xref>, <xref rid="b0665" ref-type="bibr">[133]</xref>, <xref rid="b0670" ref-type="bibr">[134]</xref>. However, there is still a need to understand the relevant receptors and downstream cellular signaling responses and biodistribution profiles in conjugation with specific antiviral and vaccine formulations <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0655" ref-type="bibr">[131]</xref>.</p></sec></sec><sec id="s0155"><title>Discussion: lessons learned from pandemics</title><p id="p0780">During the pandemics of influenza virus, several difficulties and challenges were faced in finding the right antiviral treatment as the approved therapeutics were designed only for acute, common, and uncomplicated cases of influenza infection to reduce symptoms <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>. Rapid resistance development to antiviral drugs further complicated the problem and caused the longevity of the pandemic era <xref rid="b0215" ref-type="bibr">[43]</xref>. The scientific community was greatly concerned about the resistance and under such conditions, drugs, such as oseltamivir, zanamivir, and peramivir are allowed for seriously ill patients and dosages are limited for acute patients. Oseltamivir and zanamivir were FDA approved in 1999. Peramivir was approved in 2014 with emergency use authorization in 2009 <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0675" ref-type="bibr">[135]</xref>. Moreover, some drug administration routes were also sorted out for severely ill patients such as: oral, intranasal, intravenous, intramuscular. subcutaneous, inhalation, topical and rectal routes. it was also sorted that the specific route of administration for influenza treatment depends on the type of medication, the patient's condition, and the desired effect of the treatment.</p><p id="p0785">New mechanisms have been proposed in terms of therapeutics against host-directed viral replication, such as indirect viral inhibitor. They interfere with the host intracellular process required for viral replication and modulate host immune responses <xref rid="b0680" ref-type="bibr">[136]</xref>, <xref rid="b0685" ref-type="bibr">[137]</xref>. However, no specific approved drugs have come forward with this mechanism of action, thus more work is needed in this direction. Resistance against antiviral therapies, high mutation rates among influenza viruses, and inability to completely deal with disease symptoms by certain drugs, were the major reasons behind the concept of combination therapy <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0415" ref-type="bibr">[83]</xref>, <xref rid="b0680" ref-type="bibr">[136]</xref>, <xref rid="b0685" ref-type="bibr">[137]</xref>. The basic principle is to aim multiple targets including viral replication machinery, host cell machinery needed for viral replication, adjusting pharmacokinetic potentials of different drug regimens, dealing with the rapid virus resistance patterns and managing immune regulation, especially in complicated immunocompromised case <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0005" ref-type="bibr">[1]</xref>. These combination therapies have been employed for other bacterial and viral diseases such as human immunodeficiency virus (HIV)- where combination therapy under the name of highly active antiretroviral therapy (HAART) has been in trials for a long <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0410" ref-type="bibr">[82]</xref>.</p><p id="p0790">The main benefits that are linked with the combination approach are the increase in survival rates, generation of the synergistic and additive effects of combination drugs and reduction in the dosages required for a single drug <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>. A decrease in a single drug dosage also decreases the dose-dependent toxicity and side effects associated with drug usage and reduces the mutational and resistance development among viral strains as well. Different drug combinations are thus being proposed and checked in clinical trials such as double, and triple drug combinations <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0305" ref-type="bibr">[61]</xref>. However, the human&#8217;s trials for these therapies are limited owing to the uncertainty associated with viral mutation and drug resistance [<xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>. Therefore, it is pertinent to design clinical research trials to specifically evaluate the efficacy of combination therapies in a bigger range of animal models.</p><p id="p0795">Most applicable, licensed, and approved vaccines worldwide are based on traditional methods devised more than 50&#160;years ago, which are facing challenges in terms of viral heterogenicity and the inability to target all virus types by a single vaccine candidate <xref rid="b0160" ref-type="bibr">[32]</xref>. WHO and CDC regulates semi-annual recommendations to induce strain-specific vaccination trials and clinical practices for different regions of the world <xref rid="b0405" ref-type="bibr">[81]</xref>, <xref rid="b0690" ref-type="bibr">[138]</xref>. Thus, vaccines are manufactured annually with the updates in line with the exhibited viral mutations in influenza subtypes. The annual practices based on classic vaccine candidates make it difficult to initiate a novel vaccine practice because of the acquaintance with the familiar, cost-effective, consistent, and largely accepted practices of vaccination on old therapeutics <xref rid="b0695" ref-type="bibr">[139]</xref>, <xref rid="b0700" ref-type="bibr">[140]</xref>. Moreover, the ongoing vaccine trials also face challenges in terms of comparative analyses and placebo models based on traditional therapeutics. However, there is a need to regulate the modern vaccination design if we want to overcome yearly vaccination updates for the coming year ahead. The focus of future vaccination trials should be kept on reducing the morbidity with chronic influenza and mortality rates. For this purpose, regular clinical trials should be carried out to validate the potential universal vaccine candidates.</p></sec><sec id="s0160"><title>Conclusion</title><p id="p0800">The past two decades, especially in the time after the pandemics of 2009&#8211;2010, have presented several challenges associated with influenza therapy. For the cause, certain therapies came to the surface as discussed in this review article. These antiviral therapeutics are effective candidates, but all have associated limited efficacy and some side effects and other complications. Moreover, the problem of viral mutations and drug resistance is common to all the discussed therapeutic interventions. Under this scenario, it is essential to practice more on combination therapeutic approaches. Additionally, trials should be conducted to bring out-of-the-box solutions and create competitive therapeutic options that may be based on data from previous therapeutic trials coupled with the latest development in biotechnology.</p><p id="p0805">On the other hand, the recent advances in vaccinology, pharmaceutics, and biotechnology are still stuck in experimental phases. The major issues besides the continuously mutating nature of the virus may involve the technicalities, clinical approvals, ethical considerations, logistic gaps, financial lacking, and regulatory deviations that delay the overall approval procedures. The need of the time is to improvise more qualitative and quantitative research designs and clinical practices to fasten the vaccine approval on an international level. For that, more clinical experiments should be conducted to establish antiviral therapeutics and vaccine efficacious profiles in humans.</p><p id="p0810">
<bold>Funding</bold>
</p><p id="p0815">M.A. work is supported by Ragnar S&#246;derberg Foundation (M13/18) and Swedish Research Council (2018-02266).</p></sec><sec id="s0165"><title>CRediT authorship contribution statement</title><p id="p0820"><bold>Shiza Malik:</bold> Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing. <bold>Muhammad Asghar:</bold> Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing. <bold>Yasir Waheed:</bold> Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0825">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Govorkova</surname><given-names>E.A.</given-names></name></person-group><article-title>Continuing challenges in influenza</article-title><source>Ann N Y Acad Sci</source><volume>1323</volume><issue>1</issue><year>2014</year><fpage>115</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">24891213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nyas.12462</pub-id><pub-id pub-id-type="pmcid">PMC4159436</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Koszalka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tilmanis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>Influenza antivirals currently in late-phase clinical trial</article-title><source>Influenza Other Respir Viruses</source><volume>11</volume><issue>3</issue><year>2017</year><fpage>240</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">28146320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/irv.12446</pub-id><pub-id pub-id-type="pmcid">PMC5410715</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Memoli</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Athota</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Czajkowski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bristol</surname><given-names>T.</given-names></name><name name-style="western"><surname>Proudfoot</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts</article-title><source>Clin Infect Dis</source><volume>58</volume><issue>2</issue><year>2014</year><fpage>214</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">24186906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cit725</pub-id><pub-id pub-id-type="pmcid">PMC3871797</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Oshansky</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Gartland</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Jeevan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roddam</surname><given-names>P.L.</given-names></name><etal/></person-group><article-title>Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load</article-title><source>Am J Respir Crit Care Med</source><volume>189</volume><issue>4</issue><year>2014</year><fpage>449</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">24308446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201309-1616OC</pub-id><pub-id pub-id-type="pmcid">PMC3977720</pub-id></element-citation></ref><ref id="b0025"><label>5</label><mixed-citation publication-type="other" id="h0025">Cole SL et al. M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight 2017;2(7).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.91868</pub-id><pub-id pub-id-type="pmcid">PMC5374077</pub-id><pub-id pub-id-type="pmid">28405622</pub-id></mixed-citation></ref><ref id="b0030"><label>6</label><mixed-citation publication-type="other" id="h0030">Stramer SL et al. Sensitive detection assays for influenza RNA do not reveal viremia in US blood donors. J Infect Diseases 2012;205(6):886&#8211;894.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jir863</pub-id><pub-id pub-id-type="pmcid">PMC3282565</pub-id><pub-id pub-id-type="pmid">22293429</pub-id></mixed-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Tellier</surname><given-names>R.</given-names></name></person-group><article-title>Review of aerosol transmission of influenza A virus</article-title><source>Emerg Infect Dis</source><volume>12</volume><issue>11</issue><year>2006</year><fpage>1657</fpage><lpage>1662</lpage><pub-id pub-id-type="pmid">17283614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1211.060426</pub-id><pub-id pub-id-type="pmcid">PMC3372341</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.G.</given-names></name></person-group><article-title>Respiratory epithelial cells in innate immunity to influenza virus infection</article-title><source>Cell Tissue Res</source><volume>343</volume><issue>1</issue><year>2011</year><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">20848130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00441-010-1043-z</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="book" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Kilbourne</surname><given-names>E.D.</given-names></name></person-group><part-title>Influenza</part-title><year>2012</year><publisher-name>Springer Science &amp; Business Media</publisher-name></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Hannoun</surname><given-names>C.</given-names></name></person-group><article-title>The evolving history of influenza viruses and influenza vaccines</article-title><source>Expert Rev Vac</source><volume>12</volume><issue>9</issue><year>2013</year><fpage>1085</fpage><lpage>1094</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2013.824709</pub-id><pub-id pub-id-type="pmid">24024871</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name></person-group><article-title>Influenza therapeutics in clinical practice&#8212;challenges and recent advances</article-title><source>Cold Spring Harb Perspect Med</source><volume>11</volume><issue>4</issue><year>2021</year><fpage>a038463</fpage><pub-id pub-id-type="pmid">32041763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a038463</pub-id><pub-id pub-id-type="pmcid">PMC8015700</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Ison</surname><given-names>M.G.</given-names></name></person-group><article-title>Antivirals and resistance: influenza virus</article-title><source>Curr Opin Virol</source><volume>1</volume><issue>6</issue><year>2011</year><fpage>563</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">22440914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2011.09.002</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Manicassamy</surname><given-names>B.</given-names></name></person-group><article-title>Broadly protective strategies against influenza viruses: universal vaccines and therapeutics</article-title><source>Front Microbiol</source><volume>11</volume><year>2020</year><fpage>135</fpage><pub-id pub-id-type="pmid">32117155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2020.00135</pub-id><pub-id pub-id-type="pmcid">PMC7020694</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>Antiviral therapy for the next influenza pandemic</article-title><source>Trop Med Infect Dis</source><volume>4</volume><issue>2</issue><year>2019</year><fpage>67</fpage><pub-id pub-id-type="pmid">31003518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/tropicalmed4020067</pub-id><pub-id pub-id-type="pmcid">PMC6630704</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Lycett</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Duchatel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Digard</surname><given-names>P.</given-names></name></person-group><article-title>A brief history of bird flu</article-title><source>Philos Trans R Soc B</source><volume>374</volume><issue>1775</issue><year>2019</year><fpage>20180257</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1098/rstb.2018.0257</pub-id><pub-id pub-id-type="pmcid">PMC6553608</pub-id><pub-id pub-id-type="pmid">31056053</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Lokhande</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>More</surname><given-names>S.S.</given-names></name></person-group><article-title>A comprehensive review on: swine flu</article-title><source>Asian J Res Pharmaceut Sci</source><volume>9</volume><issue>4</issue><year>2019</year><fpage>282</fpage><lpage>287</lpage></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="book" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Nandy</surname><given-names>A.</given-names></name><etal/></person-group><part-title>Alignment-Free Analyses of Nucleic Acid Sequences Using Graphical Representation (with Special Reference to Pandemic Bird Flu and Swine Flu)</part-title><source>in <italic toggle="yes">Synthetic Biology</italic></source><year>2018</year><fpage>141</fpage><lpage>188</lpage></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Vanderlinden</surname><given-names>E.</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>L.</given-names></name></person-group><article-title>Emerging antiviral strategies to interfere with influenza virus entry</article-title><source>Med Res Rev</source><volume>34</volume><issue>2</issue><year>2014</year><fpage>301</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">23801557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21289</pub-id><pub-id pub-id-type="pmcid">PMC7168512</pub-id></element-citation></ref><ref id="b0095"><label>19</label><mixed-citation publication-type="other" id="h0095">Wai HS, Mandalay M, Myint WW, Meiktila M, Win EP. Detection H5N1 Flu for Chicken Using Feature Extraction.</mixed-citation></ref><ref id="b0100"><label>20</label><mixed-citation publication-type="other" id="h0100">Duwe S. Influenza viruses&#8211;antiviral therapy and resistance. GMS Infect Dis 2017;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3205/id000030</pub-id><pub-id pub-id-type="pmcid">PMC6301739</pub-id><pub-id pub-id-type="pmid">30671326</pub-id></mixed-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Loregian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mercorelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nannetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Compagnin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pal&#249;</surname><given-names>G.</given-names></name></person-group><article-title>Antiviral strategies against influenza virus: towards new therapeutic approaches</article-title><source>Cell Mol Life Sci</source><volume>71</volume><issue>19</issue><year>2014</year><fpage>3659</fpage><lpage>3683</lpage><pub-id pub-id-type="pmid">24699705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-014-1615-2</pub-id><pub-id pub-id-type="pmcid">PMC11114059</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.D.</given-names></name></person-group><article-title>Emerging influenza antiviral resistance threats</article-title><source>J Infect Dis</source><volume>203</volume><issue>1</issue><year>2011</year><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">21148489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiq012</pub-id><pub-id pub-id-type="pmcid">PMC3086431</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Gebre</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Carfi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Novel approaches for vaccine development</article-title><source>Cell</source><volume>184</volume><issue>6</issue><year>2021</year><fpage>1589</fpage><lpage>1603</lpage><pub-id pub-id-type="pmid">33740454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.02.030</pub-id><pub-id pub-id-type="pmcid">PMC8049514</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Kreijtz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name></person-group><article-title>Immune responses to influenza virus infection</article-title><source>Virus Res</source><volume>162</volume><issue>1&#8211;2</issue><year>2011</year><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">21963677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2011.09.022</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Petrova</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>C.A.</given-names></name></person-group><article-title>The evolution of seasonal influenza viruses</article-title><source>Nat Rev Microbiol</source><volume>16</volume><issue>1</issue><year>2018</year><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">29081496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro.2017.118</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Peteranderl</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmoldt</surname><given-names>C.</given-names></name></person-group><article-title>Human influenza virus infections</article-title><source>Semin Respir Crit Care Med</source><volume>37</volume><issue>04</issue><year>2016</year><fpage>487</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">27486731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0036-1584801</pub-id><pub-id pub-id-type="pmcid">PMC7174870</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Barik</surname><given-names>S.</given-names></name></person-group><article-title>New treatments for influenza</article-title><source>BMC Med</source><volume>10</volume><issue>1</issue><year>2012</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22973873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1741-7015-10-104</pub-id><pub-id pub-id-type="pmcid">PMC3523090</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name name-style="western"><surname>Steel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lowen</surname><given-names>A.C.</given-names></name></person-group><article-title>Influenza A virus reassortment</article-title><source>Influenza Pathogenesis and Control-Volume</source><volume>I</volume><year>2014</year><fpage>377</fpage><lpage>401</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/82_2014_395</pub-id><pub-id pub-id-type="pmid">25007845</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Vemula</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hewlett</surname><given-names>I.</given-names></name></person-group><article-title>Current approaches for diagnosis of influenza virus infections in humans</article-title><source>Viruses</source><volume>8</volume><issue>4</issue><year>2016</year><fpage>96</fpage><pub-id pub-id-type="pmid">27077877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v8040096</pub-id><pub-id pub-id-type="pmcid">PMC4848591</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S.-S.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Traditional and new influenza vaccines</article-title><source>Clin Microbiol Rev</source><volume>26</volume><issue>3</issue><year>2013</year><fpage>476</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">23824369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CMR.00097-12</pub-id><pub-id pub-id-type="pmcid">PMC3719499</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Keshavarz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirzaei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salemi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Momeni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mousavi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sadeghalvad</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Influenza vaccine: where are we and where do we go?</article-title><source>Rev Med Virol</source><volume>29</volume><issue>1</issue><year>2019</year><fpage>e2014</fpage><pub-id pub-id-type="pmid">30408280</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rmv.2014</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>Scorza</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Tsvetnitsky</surname><given-names>V.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>J.J.</given-names></name></person-group><article-title>Universal influenza vaccines: Shifting to better vaccines</article-title><source>Vaccine</source><volume>34</volume><issue>26</issue><year>2016</year><fpage>2926</fpage><lpage>2933</lpage><pub-id pub-id-type="pmid">27038130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.03.085</pub-id><pub-id pub-id-type="pmcid">PMC4899887</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Boianelli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Modeling influenza virus infection: a roadmap for influenza research</article-title><source>Viruses</source><volume>7</volume><issue>10</issue><year>2015</year><fpage>5274</fpage><lpage>5304</lpage><pub-id pub-id-type="pmid">26473911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v7102875</pub-id><pub-id pub-id-type="pmcid">PMC4632383</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Killingley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nguyen&#8208;Van&#8208;Tam</surname><given-names>J.</given-names></name></person-group><article-title>Routes of influenza transmission</article-title><source>Influenza Other Respir Viruses</source><volume>7</volume><issue>s2</issue><year>2013</year><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/irv.12080</pub-id><pub-id pub-id-type="pmcid">PMC5909391</pub-id><pub-id pub-id-type="pmid">24034483</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Sridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brokstad</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines</article-title><source>Vaccines (Basel)</source><volume>3</volume><issue>2</issue><year>2015</year><fpage>373</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">26343192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines3020373</pub-id><pub-id pub-id-type="pmcid">PMC4494344</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Tisa</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden</article-title><source>J Prev Med Hyg</source><volume>57</volume><issue>1</issue><year>2016</year><fpage>E28</fpage><pub-id pub-id-type="pmid">27346937</pub-id><pub-id pub-id-type="pmcid">PMC4910440</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Baxter</surname><given-names>D.</given-names></name></person-group><article-title>Evaluating the case for trivalent or quadrivalent influenza vaccines</article-title><source>Hum Vaccin Immunother</source><volume>12</volume><issue>10</issue><year>2016</year><fpage>2712</fpage><lpage>2717</lpage><pub-id pub-id-type="pmid">27435025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1091130</pub-id><pub-id pub-id-type="pmcid">PMC5085006</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Hook</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dubin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Flechtner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Long</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection</article-title><source>Vaccine</source><volume>37</volume><issue>4</issue><year>2019</year><fpage>664</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">30551986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.11.076</pub-id><pub-id pub-id-type="pmcid">PMC6447314</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Sparrow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Friede</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torvaldsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Newall</surname><given-names>A.T.</given-names></name></person-group><article-title>Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications</article-title><source>Vaccine</source><volume>34</volume><issue>45</issue><year>2016</year><fpage>5442</fpage><lpage>5448</lpage><pub-id pub-id-type="pmid">27622299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.08.057</pub-id><pub-id pub-id-type="pmcid">PMC5357764</pub-id></element-citation></ref><ref id="b0200"><label>40</label><mixed-citation publication-type="other" id="h0200">HSU AC, See Hv, Hansbro PM, Wark PAB. &#8220;Innate immunity to influenza in chronic airways diseases. Respirology 2012;17(8):1166&#8211;1175.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1843.2012.02200.x</pub-id><pub-id pub-id-type="pmid">22616906</pub-id></mixed-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Devi</surname><given-names>V.K.</given-names></name></person-group><article-title>In vitro evaluation of once a day chronotherapeutic drug delivery system of Gymnema sylvestre</article-title><source>Ind Crops Prod</source><volume>88</volume><year>2016</year><fpage>58</fpage><lpage>64</lpage></element-citation></ref><ref id="b0210"><label>42</label><mixed-citation publication-type="other" id="h0210">Ahearn CP, Gallo MC, Murphy TF. Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease. Pathog Dis 2017;75(4).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/femspd/ftx042</pub-id><pub-id pub-id-type="pmcid">PMC5437125</pub-id><pub-id pub-id-type="pmid">28449098</pub-id></mixed-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Boltz</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Aldridge</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Govorkova</surname><given-names>E.A.</given-names></name></person-group><article-title>Drugs in development for influenza</article-title><source>Drugs</source><volume>70</volume><issue>11</issue><year>2010</year><fpage>1349</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">20614944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11537960-000000000-00000</pub-id><pub-id pub-id-type="pmcid">PMC5558450</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez-Ram&#243;n</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhalla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chapel</surname><given-names>H.</given-names></name></person-group><article-title>Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy</article-title><source>Front Immunol</source><volume>7</volume><year>2016</year><fpage>317</fpage><pub-id pub-id-type="pmid">27597852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2016.00317</pub-id><pub-id pub-id-type="pmcid">PMC4993076</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.-K.</given-names></name><name name-style="western"><surname>Poudel</surname><given-names>B.</given-names></name></person-group><article-title>Tools to detect influenza virus</article-title><source>Yonsei Med J</source><volume>54</volume><issue>3</issue><year>2013</year><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">23549796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3349/ymj.2013.54.3.560</pub-id><pub-id pub-id-type="pmcid">PMC3635619</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Dunning</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name></person-group><article-title>Antiviral combinations for severe influenza</article-title><source>Lancet Infect Dis</source><volume>14</volume><issue>12</issue><year>2014</year><fpage>1259</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">25213733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(14)70821-7</pub-id><pub-id pub-id-type="pmcid">PMC7164787</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Paul Glezen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmier</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Oxford</surname><given-names>J.</given-names></name></person-group><article-title>The burden of influenza B: a structured literature review</article-title><source>Am J Public Health</source><volume>103</volume><issue>3</issue><year>2013</year><fpage>e43</fpage><lpage>e51</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2012.301137</pub-id><pub-id pub-id-type="pmcid">PMC3673513</pub-id><pub-id pub-id-type="pmid">23327249</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Eisfeld</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>At the centre: influenza A virus ribonucleoproteins</article-title><source>Nat Rev Microbiol</source><volume>13</volume><issue>1</issue><year>2015</year><fpage>28</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">25417656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro3367</pub-id><pub-id pub-id-type="pmcid">PMC5619696</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Bhatia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dimde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haag</surname><given-names>R.</given-names></name></person-group><article-title>Multivalent glycoconjugates as vaccines and potential drug candidates</article-title><source>Medchemcomm</source><volume>5</volume><issue>7</issue><year>2014</year><fpage>862</fpage><lpage>878</lpage></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Toots</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plemper</surname><given-names>R.K.</given-names></name></person-group><article-title>Next-generation direct-acting influenza therapeutics</article-title><source>Transl Res</source><volume>220</volume><year>2020</year><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">32088166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2020.01.005</pub-id><pub-id pub-id-type="pmcid">PMC7102518</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase</article-title><source>Virol J</source><volume>10</volume><issue>1</issue><year>2013</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">24261589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-10-321</pub-id><pub-id pub-id-type="pmcid">PMC3842836</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Chairat</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tarning</surname><given-names>J.</given-names></name><name name-style="western"><surname>White</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Lindegardh</surname><given-names>N.</given-names></name></person-group><article-title>Pharmacokinetic Properties ofAnti-Influenza Neuraminidase Inhibitors</article-title><source>J Clin Pharmacol</source><volume>53</volume><issue>2</issue><year>2013</year><fpage>119</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">23436258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270012440280</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Samson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pizzorno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abed</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Influenza virus resistance to neuraminidase inhibitors</article-title><source>Antiviral Res</source><volume>98</volume><issue>2</issue><year>2013</year><fpage>174</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">23523943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2013.03.014</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Burnham</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Baranovich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Govorkova</surname><given-names>E.A.</given-names></name></person-group><article-title>Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance</article-title><source>Antiviral Res</source><volume>100</volume><issue>2</issue><year>2013</year><fpage>520</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">24013000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2013.08.023</pub-id><pub-id pub-id-type="pmcid">PMC3850058</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>Kashiwagi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza</article-title><source>Rev Infect Dis</source><volume>63</volume><issue>3</issue><year>2016</year><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciw255</pub-id><pub-id pub-id-type="pmcid">PMC4946013</pub-id><pub-id pub-id-type="pmid">27118785</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Ikematsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>N.</given-names></name></person-group><article-title>Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza</article-title><source>Expert Rev Anti Infect Ther</source><volume>9</volume><issue>10</issue><year>2011</year><fpage>851</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">21973296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/eri.11.112</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="book" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Fage</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carbonneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abed</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name></person-group><part-title>Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors</part-title><year>2017</year><publisher-name>SAGE Publications Sage UK</publisher-name><publisher-loc>London, England</publisher-loc><pub-id pub-id-type="doi" assigning-authority="pmc">10.3851/IMP3158</pub-id><pub-id pub-id-type="pmid">29082897</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Sugaya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>Y.</given-names></name></person-group><article-title>Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection</article-title><source>Antimicrob Agents Chemother</source><volume>54</volume><issue>6</issue><year>2010</year><fpage>2575</fpage><lpage>2582</lpage><pub-id pub-id-type="pmid">20368393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01755-09</pub-id><pub-id pub-id-type="pmcid">PMC2876358</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>M.</given-names></name></person-group><article-title>Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza</article-title><source>Antivir Chem Chemother</source><volume>21</volume><issue>2</issue><year>2010</year><fpage>71</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">21107016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3851/IMP1688</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Shindo</surname><given-names>N.</given-names></name></person-group><article-title>Influenza virus polymerase inhibitors in clinical development</article-title><source>Curr Opin Infect Dis</source><volume>32</volume><issue>2</issue><year>2019</year><fpage>176</fpage><pub-id pub-id-type="pmid">30724789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QCO.0000000000000532</pub-id><pub-id pub-id-type="pmcid">PMC6416007</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Mifsud</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>Antivirals targeting the polymerase complex of influenza viruses</article-title><source>Antiviral Res</source><volume>169</volume><year>2019</year><object-id pub-id-type="publisher-id">104545</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2019.104545</pub-id><pub-id pub-id-type="pmid">31247246</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Muratore</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase</article-title><source>Proc Natl Acad Sci</source><volume>109</volume><issue>16</issue><year>2012</year><fpage>6247</fpage><lpage>6252</lpage><pub-id pub-id-type="pmid">22474359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1119817109</pub-id><pub-id pub-id-type="pmcid">PMC3341009</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase</article-title><source>Sci Rep</source><volume>6</volume><issue>1</issue><year>2016</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">26956222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep22880</pub-id><pub-id pub-id-type="pmcid">PMC4783701</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives</article-title><source>J Med Chem</source><volume>60</volume><issue>9</issue><year>2017</year><fpage>3533</fpage><lpage>3551</lpage><pub-id pub-id-type="pmid">28118010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.6b01227</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Stevaert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>L.</given-names></name></person-group><article-title>The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design</article-title><source>Med Res Rev</source><volume>36</volume><issue>6</issue><year>2016</year><fpage>1127</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">27569399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21401</pub-id><pub-id pub-id-type="pmcid">PMC5108440</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Noshi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit</article-title><source>Antiviral Res</source><volume>160</volume><year>2018</year><fpage>109</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">30316915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2018.10.008</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Papp</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles</article-title><source>Small</source><volume>6</volume><issue>24</issue><year>2010</year><fpage>2900</fpage><lpage>2906</lpage><pub-id pub-id-type="pmid">21104827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201001349</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>Kadam</surname><given-names>R.U.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol</article-title><source>Proc Natl Acad Sci</source><volume>114</volume><issue>2</issue><year>2017</year><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">28003465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1617020114</pub-id><pub-id pub-id-type="pmcid">PMC5240704</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name name-style="western"><surname>Kadam</surname><given-names>R.U.</given-names></name><etal/></person-group><article-title>Potent peptidic fusion inhibitors of influenza virus</article-title><source>Science</source><volume>358</volume><issue>6362</issue><year>1979, 2017,</year><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan0516</pub-id><pub-id pub-id-type="pmcid">PMC5659926</pub-id><pub-id pub-id-type="pmid">28971971</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name name-style="western"><surname>Matsubara</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy</article-title><source>J Med Chem</source><volume>53</volume><issue>11</issue><year>2010</year><fpage>4441</fpage><lpage>4449</lpage><pub-id pub-id-type="pmid">20476787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm1002183</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Chaisri</surname><given-names>U.</given-names></name><name name-style="western"><surname>Chaicumpa</surname><given-names>W.</given-names></name></person-group><article-title>Evolution of therapeutic antibodies, influenza virus biology, influenza, and influenza immunotherapy</article-title><source>Biomed Res Int</source><volume>2018</volume><year>2018</year><fpage>2018</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/9747549</pub-id><pub-id pub-id-type="pmcid">PMC5994580</pub-id><pub-id pub-id-type="pmid">29998138</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name></person-group><article-title>The cytokine storm of severe influenza and development of immunomodulatory therapy</article-title><source>Cell Mol Immunol</source><volume>13</volume><issue>1</issue><year>2016</year><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26189369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2015.74</pub-id><pub-id pub-id-type="pmcid">PMC4711683</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weir</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>O.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines</article-title><source>Influenza Other Respir Viruses</source><volume>14</volume><issue>2</issue><year>2020</year><fpage>237</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">31837101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/irv.12706</pub-id><pub-id pub-id-type="pmcid">PMC7040967</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maity</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varadarajan</surname><given-names>R.</given-names></name></person-group><article-title>Broadly neutralizing antibodies for therapy of viral infections</article-title><source>Antibody Technol J</source><volume>6</volume><year>2016</year><fpage>1</fpage></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name name-style="western"><surname>Nachbagauer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>Universal influenza virus vaccines and therapeutic antibodies</article-title><source>Clin Microbiol Infect</source><volume>23</volume><issue>4</issue><year>2017</year><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">28216325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2017.02.009</pub-id><pub-id pub-id-type="pmcid">PMC5389886</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Nogales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Topham</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Sobrido</surname><given-names>L.</given-names></name></person-group><article-title>Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA)</article-title><source>Vaccine</source><volume>33</volume><issue>30</issue><year>2015</year><fpage>3562</fpage><lpage>3570</lpage><pub-id pub-id-type="pmid">26044496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.05.049</pub-id><pub-id pub-id-type="pmcid">PMC4480155</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Identification of the I38T PA substitution as a resistance marker for next-generation influenza virus endonuclease inhibitors</article-title><source>MBio</source><volume>9</volume><issue>2</issue><year>2018</year><fpage>e00430</fpage><lpage>e00518</lpage><pub-id pub-id-type="pmid">29691337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00430-18</pub-id><pub-id pub-id-type="pmcid">PMC5915737</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name name-style="western"><surname>Rogolino</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease</article-title><source>J Biol Inorg Chem</source><volume>20</volume><issue>7</issue><year>2015</year><fpage>1109</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">26323352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00775-015-1292-0</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name name-style="western"><surname>Radosevic</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Virtual screen for repurposing of drugs for candidate influenza a M2 ion-channel inhibitors</article-title><source>Front Cell Infect Microbiol</source><volume>9</volume><year>2019</year><fpage>67</fpage><pub-id pub-id-type="pmid">30972303</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2019.00067</pub-id><pub-id pub-id-type="pmcid">PMC6443897</pub-id></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name name-style="western"><surname>Ichinohe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Influenza virus activates inflammasomes via its intracellular M2 ion channel</article-title><source>Nat Immunol</source><volume>11</volume><issue>5</issue><year>2010</year><fpage>404</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">20383149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.1861</pub-id><pub-id pub-id-type="pmcid">PMC2857582</pub-id></element-citation></ref><ref id="b0405"><label>81</label><element-citation publication-type="journal" id="h0405"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Crank</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Shiver</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>Next-generation influenza vaccines: opportunities and challenges</article-title><source>Nat Rev Drug Discov</source><volume>19</volume><issue>4</issue><year>2020</year><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">32060419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-019-0056-x</pub-id><pub-id pub-id-type="pmcid">PMC7223957</pub-id></element-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name name-style="western"><surname>van der Vries</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schutten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fraaij</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.</given-names></name></person-group><article-title>Influenza virus resistance to antiviral therapy</article-title><source>Adv Pharmacol</source><volume>67</volume><year>2013</year><fpage>217</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">23886002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-405880-4.00006-8</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name name-style="western"><surname>Bajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hutvagner</surname><given-names>G.</given-names></name></person-group><article-title>RNA-based therapeutics: from antisense oligonucleotides to miRNAs</article-title><source>Cells</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>137</fpage><pub-id pub-id-type="pmid">31936122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9010137</pub-id><pub-id pub-id-type="pmcid">PMC7016530</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name name-style="western"><surname>Scorza</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name></person-group><article-title>New kids on the block: RNA-based influenza virus vaccines</article-title><source>Vaccines (Basel)</source><volume>6</volume><issue>2</issue><year>2018</year><fpage>20</fpage><pub-id pub-id-type="pmid">29614788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines6020020</pub-id><pub-id pub-id-type="pmcid">PMC6027361</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name name-style="western"><surname>Bathula</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Popova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.</given-names></name></person-group><article-title>&#8220;Delivery vehicles for self-amplifying RNA</article-title><source>Messenger RNA Therapeutics Springer</source><year>2022</year><fpage>355</fpage><lpage>370</lpage></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name name-style="western"><surname>Papukashvili</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rcheulishvili</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.G.</given-names></name></person-group><article-title>Self-Amplifying RNA Approach for Protein Replacement Therapy</article-title><source>Int J Mol Sci</source><volume>23</volume><issue>21</issue><year>2022</year><fpage>12884</fpage><pub-id pub-id-type="pmid">36361673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms232112884</pub-id><pub-id pub-id-type="pmcid">PMC9655356</pub-id></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name name-style="western"><surname>Paules</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>Chasing seasonal influenza&#8212;the need for a universal influenza vaccine</article-title><source>N Engl J Med</source><volume>378</volume><issue>1</issue><year>2018</year><fpage>7</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">29185857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp1714916</pub-id></element-citation></ref><ref id="b0440"><label>88</label><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Steigbigel</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name></person-group><article-title>Targeting pandemic influenza: a primer on influenza antivirals and drug resistance</article-title><source>J Antimicrob Chemother</source><volume>65</volume><issue>6</issue><year>2010</year><fpage>1086</fpage><lpage>1093</lpage><pub-id pub-id-type="pmid">20375034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkq100</pub-id></element-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name name-style="western"><surname>Sellers</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>W.A.</given-names></name></person-group><article-title>The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection</article-title><source>Influenza Other Respir Viruses</source><volume>11</volume><issue>5</issue><year>2017</year><fpage>372</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">28745014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/irv.12470</pub-id><pub-id pub-id-type="pmcid">PMC5596521</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>Influenza vaccine immunology</article-title><source>Immunol Rev</source><volume>239</volume><issue>1</issue><year>2011</year><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">21198671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2010.00974.x</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name name-style="western"><surname>Hashem</surname><given-names>A.M.</given-names></name></person-group><article-title>Prospects of HA-based universal influenza vaccine</article-title><source>Biomed Res Int</source><year>2015</year><fpage>2015</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/414637</pub-id><pub-id pub-id-type="pmcid">PMC4345066</pub-id><pub-id pub-id-type="pmid">25785268</pub-id></element-citation></ref><ref id="b0460"><label>92</label><mixed-citation publication-type="other" id="h0460">M&#252;ller KH, Kakkola L, Nagaraj AS, Cheltsov Av, Anastasina M, Kainov DE. Emerging cellular targets for influenza antiviral agents. Trends Pharmacol Sci 2012;33(2):89&#8211;99.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2011.10.004</pub-id><pub-id pub-id-type="pmid">22196854</pub-id></mixed-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>Influenza vaccines for the future</article-title><source>N Engl J Med</source><volume>363</volume><issue>21</issue><year>2010</year><fpage>2036</fpage><lpage>2044</lpage><pub-id pub-id-type="pmid">21083388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1002842</pub-id></element-citation></ref><ref id="b0470"><label>94</label><mixed-citation publication-type="other" id="h0470">Clar C, Oseni Z, Flowers N, Keshtkar&#8208;Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database of Systematic Reviews, no. 5, 2015.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD005050.pub3</pub-id><pub-id pub-id-type="pmcid">PMC8511741</pub-id><pub-id pub-id-type="pmid">25940444</pub-id></mixed-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Influenza vaccine effectiveness in the United States during the 2015&#8211;2016 season</article-title><source>N Engl J Med</source><volume>377</volume><issue>6</issue><year>2017</year><fpage>534</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">28792867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1700153</pub-id><pub-id pub-id-type="pmcid">PMC5727917</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo</surname><given-names>M.M.G.</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>M.J.</given-names></name></person-group><article-title>Immunobiology of influenza vaccines</article-title><source>Chest</source><volume>143</volume><issue>2</issue><year>2013</year><fpage>502</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">23381315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.12-1711</pub-id><pub-id pub-id-type="pmcid">PMC3619640</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name name-style="western"><surname>Eichelberger</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Monto</surname><given-names>A.S.</given-names></name></person-group><article-title>Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection</article-title><source>J Infect Dis</source><volume>219</volume><year>2019</year><fpage>S75</fpage><lpage>S80</lpage><pub-id pub-id-type="pmid">30715357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz017</pub-id><pub-id pub-id-type="pmcid">PMC7325326</pub-id></element-citation></ref><ref id="b0490"><label>98</label><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name name-style="western"><surname>Jagadesh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salam</surname><given-names>A.A.A.</given-names></name><name name-style="western"><surname>Mudgal</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Arunkumar</surname><given-names>G.</given-names></name></person-group><article-title>Influenza virus neuraminidase (NA): a target for antivirals and vaccines</article-title><source>Arch Virol</source><volume>161</volume><issue>8</issue><year>2016</year><fpage>2087</fpage><lpage>2094</lpage><pub-id pub-id-type="pmid">27255748</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00705-016-2907-7</pub-id></element-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Mohamed Alitheen</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>W.B.</given-names></name></person-group><article-title>M2e-based influenza vaccines with nucleoprotein a review</article-title><source>Vaccines (Basel)</source><volume>9</volume><issue>7</issue><year>2021</year><fpage>739</fpage><pub-id pub-id-type="pmid">34358155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9070739</pub-id><pub-id pub-id-type="pmcid">PMC8310010</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name name-style="western"><surname>Turley</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a recombinant M2e&#8211;flagellin influenza vaccine (STF2. 4xM2e) in healthy adults</article-title><source>Vaccine</source><volume>29</volume><issue>32</issue><year>2011</year><fpage>5145</fpage><lpage>5152</lpage><pub-id pub-id-type="pmid">21624416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.05.041</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge</article-title><source>Mol Ther</source><volume>18</volume><issue>12</issue><year>2010</year><fpage>2182</fpage><lpage>2188</lpage><pub-id pub-id-type="pmid">20877342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2010.202</pub-id><pub-id pub-id-type="pmcid">PMC2997593</pub-id></element-citation></ref><ref id="b0510"><label>102</label><element-citation publication-type="journal" id="h0510"><person-group person-group-type="author"><name name-style="western"><surname>Saelens</surname><given-names>X.</given-names></name></person-group><article-title>The role of matrix protein 2 ectodomain in the development of universal influenza vaccines</article-title><source>J Infect Dis</source><volume>219</volume><year>2019</year><fpage>S68</fpage><lpage>S74</lpage><pub-id pub-id-type="pmid">30715367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz003</pub-id><pub-id pub-id-type="pmcid">PMC6452325</pub-id></element-citation></ref><ref id="b0515"><label>103</label><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret</article-title><source>PLoS One</source><volume>5</volume><issue>3</issue><year>2010</year><fpage>e9812</fpage><pub-id pub-id-type="pmid">20352112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0009812</pub-id><pub-id pub-id-type="pmcid">PMC2843722</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name name-style="western"><surname>Mbewana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mortimer</surname><given-names>E.</given-names></name><name name-style="western"><surname>P&#234;ra</surname><given-names>F.F.P.G.</given-names></name><name name-style="western"><surname>Hitzeroth</surname><given-names>I.I.</given-names></name><name name-style="western"><surname>Rybicki</surname><given-names>E.P.</given-names></name></person-group><article-title>Production of H5N1 influenza virus matrix protein 2 ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine</article-title><source>Front Bioeng Biotechnol</source><volume>3</volume><year>2015</year><fpage>197</fpage><pub-id pub-id-type="pmid">26697423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fbioe.2015.00197</pub-id><pub-id pub-id-type="pmcid">PMC4672040</pub-id></element-citation></ref><ref id="b0525"><label>105</label><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant</article-title><source>Hum Vaccin Immunother</source><volume>11</volume><issue>2</issue><year>2015</year><fpage>397</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">25607884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/21645515.2014.995056</pub-id><pub-id pub-id-type="pmcid">PMC4514371</pub-id></element-citation></ref><ref id="b0530"><label>106</label><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name name-style="western"><surname>Piret</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management</article-title><source>Antimicrob Agents Chemother</source><volume>55</volume><issue>2</issue><year>2011</year><fpage>459</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">21078929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.00615-10</pub-id><pub-id pub-id-type="pmcid">PMC3028810</pub-id></element-citation></ref><ref id="b0535"><label>107</label><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name name-style="western"><surname>Leirs</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Bioassay development for ultrasensitive detection of influenza a nucleoprotein using digital ELISA</article-title><source>Anal Chem</source><volume>88</volume><issue>17</issue><year>2016</year><fpage>8450</fpage><lpage>8458</lpage><pub-id pub-id-type="pmid">27487722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.analchem.6b00502</pub-id></element-citation></ref><ref id="b0540"><label>108</label><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name name-style="western"><surname>Schotsaert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Inactivated influenza virus vaccines: the future of TIV and QIV</article-title><source>Curr Opin Virol</source><volume>23</volume><year>2017</year><fpage>102</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">28505524</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2017.04.005</pub-id><pub-id pub-id-type="pmcid">PMC5502789</pub-id></element-citation></ref><ref id="b0545"><label>109</label><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name name-style="western"><surname>Jaijyan</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Govindasamy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>A chemical method for generating live-attenuated, replication-defective DNA viruses for vaccine development</article-title><source>Cell Reports Methods</source><volume>2</volume><issue>9</issue><year>2022</year><object-id pub-id-type="publisher-id">100287</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.crmeth.2022.100287</pub-id><pub-id pub-id-type="pmcid">PMC9499982</pub-id><pub-id pub-id-type="pmid">36160049</pub-id></element-citation></ref><ref id="b0550"><label>110</label><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>M.P.</given-names></name></person-group><article-title>Live attenuated influenza vaccine (FluMist&#174;; Fluenz<sup>TM</sup>)</article-title><source>Drugs</source><volume>71</volume><issue>12</issue><year>2011</year><fpage>1591</fpage><lpage>1622</lpage><pub-id pub-id-type="pmid">21861544</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11206860-000000000-00000</pub-id></element-citation></ref><ref id="b0555"><label>111</label><element-citation publication-type="journal" id="h0555"><person-group person-group-type="author"><name name-style="western"><surname>Lanthier</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses</article-title><source>Vaccine</source><volume>29</volume><issue>44</issue><year>2011</year><fpage>7849</fpage><lpage>7856</lpage><pub-id pub-id-type="pmid">21816194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.07.093</pub-id><pub-id pub-id-type="pmcid">PMC3757566</pub-id></element-citation></ref><ref id="b0560"><label>112</label><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name name-style="western"><surname>Ambrose</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>M.J.</given-names></name></person-group><article-title>The rationale for quadrivalent influenza vaccines</article-title><source>Hum Vaccin Immunother</source><volume>8</volume><issue>1</issue><year>2012</year><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">22252006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.8.1.17623</pub-id><pub-id pub-id-type="pmcid">PMC3350141</pub-id></element-citation></ref><ref id="b0565"><label>113</label><element-citation publication-type="journal" id="h0565"><person-group person-group-type="author"><name name-style="western"><surname>Seibert</surname><given-names>C.W.</given-names></name><etal/></person-group><article-title>Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs</article-title><source>J Virol</source><volume>87</volume><issue>14</issue><year>2013</year><fpage>7793</fpage><lpage>7804</lpage><pub-id pub-id-type="pmid">23698296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00979-13</pub-id><pub-id pub-id-type="pmcid">PMC3700183</pub-id></element-citation></ref><ref id="b0570"><label>114</label><element-citation publication-type="journal" id="h0570"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.-H.</given-names></name><etal/></person-group><article-title>Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope</article-title><source>Virology</source><volume>550</volume><year>2020</year><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">32882637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2020.08.003</pub-id><pub-id pub-id-type="pmcid">PMC7554235</pub-id></element-citation></ref><ref id="b0575"><label>115</label><element-citation publication-type="journal" id="h0575"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name></person-group><article-title>Developments of subunit and VLP vaccines against influenza A virus</article-title><source>Virol Sin</source><volume>27</volume><issue>3</issue><year>2012</year><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">22684468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12250-012-3241-1</pub-id><pub-id pub-id-type="pmcid">PMC8218038</pub-id></element-citation></ref><ref id="b0580"><label>116</label><element-citation publication-type="journal" id="h0580"><person-group person-group-type="author"><name name-style="western"><surname>Castilho</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Mattos</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Gutarra</surname><given-names>M.L.E.</given-names></name></person-group><article-title>Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development</article-title><source>Biologics</source><volume>2</volume><issue>4</issue><year>2022</year><fpage>226</fpage><lpage>242</lpage></element-citation></ref><ref id="b0585"><label>117</label><element-citation publication-type="journal" id="h0585"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>F.-S.</given-names></name><etal/></person-group><article-title>Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization</article-title><source>J Virol</source><volume>84</volume><issue>15</issue><year>2010</year><fpage>7760</fpage><lpage>7769</lpage><pub-id pub-id-type="pmid">20484519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01849-09</pub-id><pub-id pub-id-type="pmcid">PMC2897640</pub-id></element-citation></ref><ref id="b0590"><label>118</label><element-citation publication-type="journal" id="h0590"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Mac&#237;as</surname><given-names>C.</given-names></name></person-group><article-title>Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic</article-title><source>Hum Vaccin Immunother</source><volume>8</volume><issue>3</issue><year>2012</year><fpage>411</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">22330956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.18757</pub-id><pub-id pub-id-type="pmcid">PMC3426084</pub-id></element-citation></ref><ref id="b0595"><label>119</label><mixed-citation publication-type="other" id="h0595">Grant EJ, Chen L, Quinones-Parra S, Pang K, Kedzierska K, Chen W. T-cell immunity to influenza A viruses. Crit Rev Immunol 2014;34(1).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1615/critrevimmunol.2013010019</pub-id><pub-id pub-id-type="pmid">24579700</pub-id></mixed-citation></ref><ref id="b0600"><label>120</label><element-citation publication-type="journal" id="h0600"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>A.C.L.</given-names></name><name name-style="western"><surname>Deliyannis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bharadwaj</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>D.C.</given-names></name></person-group><article-title>The design and proof of concept for a CD8+ T cell-based vaccine inducing cross-subtype protection against influenza A virus</article-title><source>Immunol Cell Biol</source><volume>91</volume><issue>1</issue><year>2013</year><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">23146941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2012.54</pub-id></element-citation></ref><ref id="b0605"><label>121</label><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name name-style="western"><surname>Lillie</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Preliminary assessment of the efficacy of a t-cell&#8211;based influenza vaccine, MVA-NP+ M1, in humans</article-title><source>Clin Infect Dis</source><volume>55</volume><issue>1</issue><year>2012</year><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">22441650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/cis327</pub-id><pub-id pub-id-type="pmcid">PMC3369564</pub-id></element-citation></ref><ref id="b0610"><label>122</label><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>L.Y.Y.</given-names></name><name name-style="western"><surname>Izzard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>A review of DNA vaccines against influenza</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>1568</fpage><pub-id pub-id-type="pmid">30038621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01568</pub-id><pub-id pub-id-type="pmcid">PMC6046547</pub-id></element-citation></ref><ref id="b0615"><label>123</label><element-citation publication-type="journal" id="h0615"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>DNA vaccines: an historical perspective and view to the future</article-title><source>Immunol Rev</source><volume>239</volume><issue>1</issue><year>2011</year><fpage>62</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">21198665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2010.00980.x</pub-id></element-citation></ref><ref id="b0620"><label>124</label><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles</article-title><source>Vaccine</source><volume>29</volume><issue>47</issue><year>2011</year><fpage>8549</fpage><lpage>8556</lpage><pub-id pub-id-type="pmid">21945253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.09.029</pub-id></element-citation></ref><ref id="b0625"><label>125</label><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M.Z.</given-names></name><etal/></person-group><article-title>Heterologous prime-boost with A (H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost</article-title><source>NPJ Vaccines</source><volume>4</volume><issue>1</issue><year>2019</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">31149353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-019-0114-8</pub-id><pub-id pub-id-type="pmcid">PMC6541649</pub-id></element-citation></ref><ref id="b0630"><label>126</label><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name name-style="western"><surname>Sabarth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Savidis-Dacho</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Maurik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Kistner</surname><given-names>O.</given-names></name></person-group><article-title>Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model</article-title><source>Vaccine</source><volume>28</volume><issue>3</issue><year>2010</year><fpage>650</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">19896446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.10.105</pub-id></element-citation></ref><ref id="b0635"><label>127</label><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs</article-title><source>Vet Res</source><volume>51</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">32646490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13567-020-00810-z</pub-id><pub-id pub-id-type="pmcid">PMC7344353</pub-id></element-citation></ref><ref id="b0640"><label>128</label><element-citation publication-type="journal" id="h0640"><person-group person-group-type="author"><name name-style="western"><surname>Kok</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>M.</given-names></name></person-group><article-title>Cross-reactivity conferred by homologous and heterologous prime-boost A/H5 influenza vaccination strategies in humans: a literature review</article-title><source>Vaccines (Basel)</source><volume>9</volume><issue>12</issue><year>2021</year><fpage>1465</fpage><pub-id pub-id-type="pmid">34960210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9121465</pub-id><pub-id pub-id-type="pmcid">PMC8708856</pub-id></element-citation></ref><ref id="b0645"><label>129</label><element-citation publication-type="journal" id="h0645"><person-group person-group-type="author"><name name-style="western"><surname>Ledgerwood</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect</article-title><source>J Infect Dis</source><volume>208</volume><issue>3</issue><year>2013</year><fpage>418</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">23633407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jit180</pub-id><pub-id pub-id-type="pmcid">PMC3699006</pub-id></element-citation></ref><ref id="b0650"><label>130</label><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>J.J.S.</given-names></name><etal/></person-group><article-title>Short-and long-term protective efficacy against clade 2.3. 4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys</article-title><source>Vaccine</source><volume>35</volume><issue>42</issue><year>2017</year><fpage>5637</fpage><lpage>5643</lpage><pub-id pub-id-type="pmid">28886943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.08.059</pub-id><pub-id pub-id-type="pmcid">PMC5659307</pub-id></element-citation></ref><ref id="b0655"><label>131</label><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.T.</given-names></name></person-group><article-title>Recent advances of vaccine adjuvants for infectious diseases</article-title><source>Immune Netw</source><volume>15</volume><issue>2</issue><year>2015</year><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">25922593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4110/in.2015.15.2.51</pub-id><pub-id pub-id-type="pmcid">PMC4411509</pub-id></element-citation></ref><ref id="b0660"><label>132</label><element-citation publication-type="journal" id="h0660"><person-group person-group-type="author"><name name-style="western"><surname>Moser</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaeser</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Weydemann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Amacker</surname><given-names>M.</given-names></name></person-group><article-title>Influenza virosomes as vaccine adjuvant and carrier system</article-title><source>Expert Rev Vaccines</source><volume>12</volume><issue>7</issue><year>2013</year><fpage>779</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">23885823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2013.811195</pub-id></element-citation></ref><ref id="b0665"><label>133</label><element-citation publication-type="journal" id="h0665"><person-group person-group-type="author"><name name-style="western"><surname>Clegg</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Roque</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Rininger</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza</article-title><source>PLoS One</source><volume>9</volume><issue>2</issue><year>2014</year><fpage>e88979</fpage><pub-id pub-id-type="pmid">24551202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0088979</pub-id><pub-id pub-id-type="pmcid">PMC3925208</pub-id></element-citation></ref><ref id="b0670"><label>134</label><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name name-style="western"><surname>Tetsutani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.J.</given-names></name></person-group><article-title>Adjuvants in influenza vaccines</article-title><source>Vaccine</source><volume>30</volume><issue>52</issue><year>2012</year><fpage>7658</fpage><lpage>7661</lpage><pub-id pub-id-type="pmid">23084848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.10.007</pub-id></element-citation></ref><ref id="b0675"><label>135</label><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.-O.</given-names></name></person-group><article-title>Inhibition of influenza virus replication by plant-derived isoquercetin</article-title><source>Antiviral Res</source><volume>88</volume><issue>2</issue><year>2010</year><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">20826184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2010.08.016</pub-id></element-citation></ref><ref id="b0680"><label>136</label><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name name-style="western"><surname>Yue</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak</article-title><source>J Med Virol</source><volume>92</volume><issue>11</issue><year>2020</year><fpage>2870</fpage><lpage>2873</lpage><pub-id pub-id-type="pmid">32530499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26163</pub-id><pub-id pub-id-type="pmcid">PMC7307028</pub-id></element-citation></ref><ref id="b0685"><label>137</label><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name name-style="western"><surname>Barello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Falc&#243;-Pegueroles</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tolotti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graffigna</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonetti</surname><given-names>L.</given-names></name></person-group><article-title>The psychosocial impact of flu influenza pandemics on healthcare workers and lessons learnt for the COVID-19 emergency: a rapid review</article-title><source>Int J Public Health</source><volume>65</volume><issue>7</issue><year>2020</year><fpage>1205</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">32888048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00038-020-01463-7</pub-id><pub-id pub-id-type="pmcid">PMC7472941</pub-id></element-citation></ref><ref id="b0690"><label>138</label><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name name-style="western"><surname>Houser</surname><given-names>K.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Influenza vaccines: challenges and solutions</article-title><source>Cell Host Microbe</source><volume>17</volume><issue>3</issue><year>2015</year><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">25766291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2015.02.012</pub-id><pub-id pub-id-type="pmcid">PMC4362519</pub-id></element-citation></ref><ref id="b0695"><label>139</label><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name name-style="western"><surname>Soema</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Kompier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amorij</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.F.A.</given-names></name></person-group><article-title>Current and next generation influenza vaccines: Formulation and production strategies</article-title><source>Eur J Pharm Biopharm</source><volume>94</volume><year>2015</year><fpage>251</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">26047796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejpb.2015.05.023</pub-id></element-citation></ref><ref id="b0700"><label>140</label><element-citation publication-type="journal" id="h0700"><person-group person-group-type="author"><name name-style="western"><surname>Osterholm</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belongia</surname><given-names>E.A.</given-names></name></person-group><article-title>Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis</article-title><source>Lancet Infect Dis</source><volume>12</volume><issue>1</issue><year>2012</year><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22032844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(11)70295-X</pub-id></element-citation></ref><ref id="b0705"><label>141</label><element-citation publication-type="journal" id="h0705"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S.-J.</given-names></name><etal/></person-group><article-title>Nanostructured glycan architecture is important in the inhibition of influenza A virus infection</article-title><source>Nat Nanotechnol</source><volume>12</volume><issue>1</issue><year>2017</year><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">27775724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2016.181</pub-id></element-citation></ref><ref id="b0710"><label>142</label><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zorofchian Moghadamtousi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abubakar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zandi</surname><given-names>K.</given-names></name></person-group><article-title>Antiviral potential of algae polysaccharides isolated from marine sources: a review</article-title><source>Biomed Res Int</source><year>2015</year><fpage>2015</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/825203</pub-id><pub-id pub-id-type="pmcid">PMC4592888</pub-id><pub-id pub-id-type="pmid">26484353</pub-id></element-citation></ref><ref id="b0715"><label>143</label><mixed-citation publication-type="other" id="h0715">Credille Cv, Chen Y, Cohen SM. Fragment-based identification of influenza endonuclease inhibitors. J Med Chem 59(13) (2016) 6444&#8211;6454.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.6b00628</pub-id><pub-id pub-id-type="pmcid">PMC4948595</pub-id><pub-id pub-id-type="pmid">27291165</pub-id></mixed-citation></ref><ref id="b0720"><label>144</label><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name name-style="western"><surname>Essilfie</surname><given-names>A.-T.</given-names></name><etal/></person-group><article-title>Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma</article-title><source>Thorax</source><volume>67</volume><issue>7</issue><year>2012</year><fpage>588</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">22387445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/thoraxjnl-2011-200160</pub-id></element-citation></ref><ref id="b0725"><label>145</label><element-citation publication-type="journal" id="h0725"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Sobrido</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies</article-title><source>J Virol</source><volume>84</volume><issue>4</issue><year>2010</year><fpage>2157</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">19939917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01433-09</pub-id><pub-id pub-id-type="pmcid">PMC2812370</pub-id></element-citation></ref><ref id="b0730"><label>146</label><element-citation publication-type="journal" id="h0730"><person-group person-group-type="author"><name name-style="western"><surname>Antoine</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Trigilio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Adelung</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>D.</given-names></name></person-group><article-title>Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection</article-title><source>Antiviral Res</source><volume>96</volume><issue>3</issue><year>2012</year><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">23047013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2012.09.020</pub-id><pub-id pub-id-type="pmcid">PMC3535478</pub-id></element-citation></ref><ref id="b0735"><label>147</label><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name name-style="western"><surname>Dispinseri</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival</article-title><source>Nat Commun</source><volume>12</volume><issue>1</issue><year>2021</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">33976165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22958-8</pub-id><pub-id pub-id-type="pmcid">PMC8113594</pub-id></element-citation></ref><ref id="b0740"><label>148</label><element-citation publication-type="journal" id="h0740"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Hemagglutinin-specific non-neutralizing antibody is essential for protection provided by inactivated and viral-vectored H7N9 avian influenza vaccines in chickens</article-title><source>Front Vet Sci</source><volume>6</volume><year>2020</year><fpage>482</fpage><pub-id pub-id-type="pmid">31998763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fvets.2019.00482</pub-id><pub-id pub-id-type="pmcid">PMC6962174</pub-id></element-citation></ref><ref id="b0745"><label>149</label><element-citation publication-type="journal" id="h0745"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>N.H.L.</given-names></name><name name-style="western"><surname>Valkenburg</surname><given-names>S.A.</given-names></name></person-group><article-title>Universally immune: how infection permissive next generation influenza vaccines may affect population immunity and viral spread</article-title><source>Viruses</source><volume>13</volume><issue>9</issue><year>2021</year><fpage>1779</fpage><pub-id pub-id-type="pmid">34578360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13091779</pub-id><pub-id pub-id-type="pmcid">PMC8472936</pub-id></element-citation></ref><ref id="b0750"><label>150</label><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Global epidemiology of human infections with variant influenza viruses, 1959&#8211;2021: A descriptive study</article-title><source>Clin Infect Dis</source><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciac168</pub-id><pub-id pub-id-type="pmid">35231106</pub-id></element-citation></ref><ref id="b0755"><label>151</label><element-citation publication-type="journal" id="h0755"><person-group person-group-type="author"><name name-style="western"><surname>Bouvier</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Lowen</surname><given-names>A.C.</given-names></name></person-group><article-title>Animal models for influenza virus pathogenesis and transmission</article-title><source>Viruses</source><volume>2</volume><issue>8</issue><year>2010</year><fpage>1530</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">21442033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v20801530</pub-id><pub-id pub-id-type="pmcid">PMC3063653</pub-id></element-citation></ref><ref id="b0760"><label>152</label><element-citation publication-type="journal" id="h0760"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Uyeki</surname><given-names>T.M.</given-names></name></person-group><article-title>Influenza virus-related critical illness: prevention, diagnosis, treatment</article-title><source>Crit Care</source><volume>23</volume><issue>1</issue><year>2019</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">31189475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13054-019-2491-9</pub-id><pub-id pub-id-type="pmcid">PMC6563376</pub-id></element-citation></ref><ref id="b0765"><label>153</label><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name name-style="western"><surname>Killingley</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The environmental deposition of influenza virus from patients infected with influenza A (H1N1) pdm09: Implications for infection prevention and control</article-title><source>J Infect Public Health</source><volume>9</volume><issue>3</issue><year>2016</year><fpage>278</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">26653976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jiph.2015.10.009</pub-id></element-citation></ref><ref id="b0770"><label>154</label><element-citation publication-type="journal" id="h0770"><person-group person-group-type="author"><name name-style="western"><surname>Gorman</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>An immunocompetent mouse model of Zika virus infection</article-title><source>Cell Host Microbe</source><volume>23</volume><issue>5</issue><year>2018</year><fpage>672</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">29746837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2018.04.003</pub-id><pub-id pub-id-type="pmcid">PMC5953559</pub-id></element-citation></ref><ref id="b0775"><label>155</label><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Garc&#237;a-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Influenza A viruses: new research developments</article-title><source>Nat Rev Microbiol</source><volume>9</volume><issue>8</issue><year>2011</year><fpage>590</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">21747392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrmicro2613</pub-id><pub-id pub-id-type="pmcid">PMC10433403</pub-id></element-citation></ref><ref id="b0780"><label>156</label><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name name-style="western"><surname>Marcelin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sandbulte</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Webby</surname><given-names>R.J.</given-names></name></person-group><article-title>Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines</article-title><source>Rev Med Virol</source><volume>22</volume><issue>4</issue><year>2012</year><fpage>267</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">22438243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rmv.1713</pub-id><pub-id pub-id-type="pmcid">PMC3389592</pub-id></element-citation></ref><ref id="b0785"><label>157</label><element-citation publication-type="journal" id="h0785"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Generation of DelNS1 influenza viruses: a strategy for optimizing live attenuated influenza vaccines</article-title><source>MBio</source><volume>10</volume><issue>5</issue><year>2019</year><comment>e02180-e0219</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02180-19</pub-id><pub-id pub-id-type="pmcid">PMC6751066</pub-id><pub-id pub-id-type="pmid">31530680</pub-id></element-citation></ref><ref id="b0790"><label>158</label><element-citation publication-type="journal" id="h0790"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread</article-title><source>J Virol</source><volume>86</volume><issue>8</issue><year>2012</year><fpage>4586</fpage><lpage>4598</lpage><pub-id pub-id-type="pmid">22318147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.07203-11</pub-id><pub-id pub-id-type="pmcid">PMC3318599</pub-id></element-citation></ref><ref id="b0795"><label>159</label><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>K.H.</given-names></name></person-group><article-title>DNA vaccines: roles against diseases</article-title><source>Germs</source><volume>3</volume><issue>1</issue><year>2013</year><fpage>26</fpage><pub-id pub-id-type="pmid">24432284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11599/germs.2013.1034</pub-id><pub-id pub-id-type="pmcid">PMC3882840</pub-id></element-citation></ref><ref id="b0800"><label>160</label><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>L.R.</given-names></name><etal/></person-group><article-title>Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin</article-title><source>Vaccine</source><volume>28</volume><issue>13</issue><year>2010</year><fpage>2565</fpage><lpage>2572</lpage><pub-id pub-id-type="pmid">20117262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.01.029</pub-id></element-citation></ref><ref id="b0805"><label>161</label><element-citation publication-type="journal" id="h0805"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>M.Y.E.</given-names></name><etal/></person-group><article-title>Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice</article-title><source>PLoS One</source><volume>9</volume><issue>4</issue><year>2014</year><fpage>e94051</fpage><pub-id pub-id-type="pmid">24714362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0094051</pub-id><pub-id pub-id-type="pmcid">PMC3979752</pub-id></element-citation></ref><ref id="b0810"><label>162</label><element-citation publication-type="journal" id="h0810"><person-group person-group-type="author"><name name-style="western"><surname>Mardanova</surname><given-names>E.S.</given-names></name><etal/></person-group><article-title>Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors</article-title><source>BMC Biotechnol</source><volume>15</volume><issue>1</issue><year>2015</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26022390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12896-015-0164-6</pub-id><pub-id pub-id-type="pmcid">PMC4446962</pub-id></element-citation></ref><ref id="b0815"><label>163</label><element-citation publication-type="journal" id="h0815"><person-group person-group-type="author"><name name-style="western"><surname>Ebrahimi</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Dabaghian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tebianian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jazi</surname><given-names>M.H.Z.</given-names></name></person-group><article-title>In contrast to conventional inactivated influenza vaccines, 4xM2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran</article-title><source>Virology</source><volume>430</volume><issue>1</issue><year>2012</year><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">22595444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2012.04.015</pub-id></element-citation></ref><ref id="b0820"><label>164</label><element-citation publication-type="journal" id="h0820"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>de Lira</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>de Matos</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.C.R.</given-names></name><name name-style="western"><surname>de Quadros</surname><given-names>M.T.</given-names></name></person-group><article-title>Therapeutic paths, care and assistance in the construction of ideas about maternity and childhood in the context of the Zika virus</article-title><source>Interface-Comunica&#231;&#227;o, Sa&#250;de, Educa&#231;&#227;o</source><volume>22</volume><year>2018</year><fpage>673</fpage><lpage>684</lpage></element-citation></ref><ref id="b0825"><label>165</label><element-citation publication-type="journal" id="h0825"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults</article-title><source>N Engl J Med</source><volume>372</volume><issue>22</issue><year>2015</year><fpage>2087</fpage><lpage>2096</lpage><pub-id pub-id-type="pmid">25916341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1501184</pub-id></element-citation></ref><ref id="b0830"><label>166</label><element-citation publication-type="journal" id="h0830"><person-group person-group-type="author"><name name-style="western"><surname>Nagatomo</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cholesteryl pullulan encapsulated TNF-&#945; nanoparticles are an effective mucosal vaccine adjuvant against influenza virus</article-title><source>Biomed Res Int</source><volume>2015</volume><year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/471468</pub-id><pub-id pub-id-type="pmcid">PMC4569761</pub-id><pub-id pub-id-type="pmid">26421290</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability" id="da005"><title>Data availability</title><p id="p0585">No data was used for the research described in the article.</p></sec></back></article></pmc-articleset>